

Highly Confidential - Subject to Further Confidentiality Review

Page 1

IN THE UNITED STATES DISTRICT COURT
FOR THE NORTHERN DISTRICT OF OHIO
EASTERN DIVISION

- - -

IN RE: NATIONAL : HON. DAN A.
PRESCRIPTION OPIATE : POLSTER
LITIGATION :
:
APPLIES TO ALL CASES : NO.
: 1:17-MD-2804

- HIGHLY CONFIDENTIAL -
SUBJECT TO FURTHER CONFIDENTIALITY REVIEW

- - -

JANUARY 22, 2019

- - -

Videotaped sworn deposition of
BRIAN LORTIE, taken pursuant to notice,
was held at McCARTER & ENGLISH, LLP,
1600 Market Street, Suite 3900,
Philadelphia, Pennsylvania, beginning at
9:06 a.m., on the above date, before
Margaret M. Reihl, a Registered
Professional Reporter, Certified
Shorthand Reporter, Certified Realtime
Reporter, and Notary Public.

- - -

GOLKOW LITIGATION SERVICES
877.370.3377 ph | 917.591.5672 fax
deps@golkow.com

Highly Confidential - Subject to Further Confidentiality Review

Page 2	Page 4
<p>1 APPEARANCES:</p> <p>2 SEEGER WEISS LLP</p> <p>3 BY: JENNIFER SCULLION, ESQUIRE</p> <p>4 ERICA KUBLY, ESQUIRE</p> <p>5 SABRINA TYJER, PARALEGAL</p> <p>6 77 Water Street</p> <p>7 New York, NY 10005</p> <p>8 (212) 584-0700</p> <p>9 jscullion@seegerweiss.com</p> <p>10 Representing the Plaintiffs</p> <p>11</p> <p>12 BRANSTETTER, STRANCH & JENNINGS, PLLC</p> <p>13 BY: JOE P. LENISKI, JR., ESQUIRE</p> <p>14 The Freedom Center</p> <p>15 223 Rosa L. Parks Avenue, Suite 200</p> <p>16 Nashville, Tennessee 37203</p> <p>17 (625) 254-8801</p> <p>18 joyl@bsjfirm.com</p> <p>19 Representing the Tennessee Plaintiffs</p> <p>20</p> <p>21 GOODELL DEVRIES LEECH & DANN, LLP</p> <p>22 BY: ROBERT LIMBACHER, ESQUIRE</p> <p>23 ADAM S. TOLIN, ESQUIRE</p> <p>24 Two Commerce Square</p> <p>2001 Market Street, Suite 3700</p> <p>Philadelphia, Pennsylvania 19103</p> <p>(267) 765-3600</p> <p>rlimbacher@gdlaw.com</p> <p>atolin@gdlaw.com</p> <p>Representing the Defendant Endo and the witness</p>	<p>1 APPEARANCES VIA TELECONFERENCE AND STREAM</p> <p>2</p> <p>3 ULMER & BERNE, LLP</p> <p>4 BY: JOSHUA A. KLARFELD, ESQUIRE</p> <p>5 1660 West 2nd Street</p> <p>6 Suite 1100</p> <p>7 Cleveland, Ohio 44113</p> <p>8 (261) 583-7000</p> <p>9 jklarfeld@ulmer.com</p> <p>10 Representing Amneal Pharmaceuticals, Inc</p> <p>11</p> <p>12 JONES DAY</p> <p>13 BY: TAYLOR GOODSPEED, ESQUIRE</p> <p>14 555 California Street, 26th Floor</p> <p>15 San Francisco, California 94104-1500</p> <p>16 (415) 875-5804</p> <p>17 tgoodspeed@jonesday.com</p> <p>18 Representing the Defendant Walmart</p> <p>19</p> <p>20 CLARK MICHIE LLP</p> <p>21 BY: BRUCE CLARK, ESQUIRE</p> <p>22 CHRISTOPHER J. MICHIE, ESQUIRE</p> <p>23 220 Alexander Street</p> <p>24 Princeton, New Jersey 08540</p> <p>(609) 423-2142</p> <p>Representing the Defendant,</p> <p>Pernix Therapeutics Holdings, Inc</p> <p>REED SMITH LLP</p> <p>BY: RYAN K. BLAKE, ESQUIRE</p> <p>Three Logan Square</p> <p>1717 Arch Street, Suite 3100</p> <p>Philadelphia, Pennsylvania 19103</p> <p>(215) 851-8280</p> <p>rblake@reedsmith.com</p> <p>Representing the Defendant AmerisourceBergen</p> <p>---</p>
Page 3	Page 5
<p>1 APPEARANCES: (cont'd)</p> <p>2</p> <p>3 PIETRAGALLO GORDON ALFANO</p> <p>4 BOSICK & RASPANTI, LLP</p> <p>5 BY: DOUGLAS K. ROSENBLUM, ESQUIRE</p> <p>6 1818 Market Street, Suite 3402</p> <p>7 Philadelphia, Pennsylvania 19103</p> <p>8 (215) 988-1464</p> <p>9 dkr@pietragallo.com</p> <p>10 Representing Cardinal Health</p> <p>11</p> <p>12 ALSO PRESENT:</p> <p>13 Carolyn M. Hazard, Litigation Counsel</p> <p>14 Endo</p> <p>15 Bill Geigert, Videographer</p> <p>16 Bradley Smith, Trial Technician</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>1 INDEX</p> <p>2 WITNESS PAGE</p> <p>3 BRIAN LORTIE</p> <p>4 By Ms. Scullion 12</p> <p>5 EXHIBITS</p> <p>6 NO DESCRIPTION PAGE</p> <p>7 Endo-</p> <p>8 Lortie-1 Notice of Deposition of</p> <p>9 Brian Lortie 13</p> <p>10 Endo-</p> <p>11 Lortie-2 Subpoena to Testify at a</p> <p>12 Deposition in a Civil Action 13</p> <p>13 Endo-</p> <p>14 Lortie-3 Resume Brian Andrew Lortie 27</p> <p>15 Endo-</p> <p>16 Lortie-4 Separation Agreement</p> <p>17 dated 6/27/16</p> <p>18 [ENDO_OPIOID_MDL_DEPONENT-</p> <p>19 000019346 through 9351] 29</p> <p>20 Endo-</p> <p>21 Lortie-5 Endo's Open Letter on the</p> <p>22 Opioid Abuse Crisis</p> <p>23 [no Bates] 45</p> <p>24 Endo-</p> <p>25 Lortie-6 Endo Independent Directors'</p> <p>26 Report, October 2018</p> <p>27 [E1588 1 through 10] 76</p> <p>28 Endo-</p> <p>29 Lortie-7 Risk Minimization Action</p> <p>30 Plan for Opana ER</p> <p>31 June 2007</p> <p>32 [ENDO-CHI_LIT-00234542</p> <p>33 through 4587] 123</p> <p>34</p>

3 (Pages 6 to 9)

Highly Confidential - Subject to Further Confidentiality Review

Page 10	Page 12
<p>1 EXHIBITS</p> <p>2 NO DESCRIPTION PAGE</p> <p>3</p> <p>4 Endo- Lortie-29 FDA letter NDA Approval NDA 201655 dated 12/9/11 [EPI001314350 through 4441] 329</p> <p>7</p> <p>8 Endo- Lortie-30 E-mails dated 5/15/12 Subject, Re: New language OER selling piece [ENDO-CHI_LIT-00206530 through 6531] 346</p> <p>11</p> <p>12 Endo- Lortie-31 E-mails dated 5/15/12 Subject, Re: New language OER selling piece [ENDO-CHI_LIT-00110100] 351</p> <p>14</p> <p>15 Endo- Lortie-32 E-mail string, top one dated 1/9/13, Subject, RE: OER Pharmacy Market Research Revised Report [END00095867 through 5870] 357</p> <p>18</p> <p>19 Endo- Lortie-33 E-mails dated 9/17/13 Subject, Re: Opana ER Prescriber [END00465847 through 5848] 365</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>1 THE VIDEOGRAPHER: Good morning.</p> <p>2 We are now on the record. My name is</p> <p>3 Bill Geigert, I am a videographer for</p> <p>4 Golkow Litigation Services. Today's</p> <p>5 date is January 22nd, 2019, and the time</p> <p>6 is 9:06 a.m. This video deposition is</p> <p>7 being held in Philadelphia, Pennsylvania</p> <p>8 in the matter of National Prescription</p> <p>9 Opiate Litigation for the U.S. District</p> <p>10 Court, Northern District of Ohio,</p> <p>11 Eastern Division.</p> <p>12 The deponent is Brian Lortie.</p> <p>13 Counsel will be noted on the</p> <p>14 stenographic record.</p> <p>15 The court reporter is Peg Reihl</p> <p>16 and she will now swear in the witness.</p> <p>17 ... BRIAN LORTIE, having been</p> <p>18 duly sworn as a witness, was examined</p> <p>19 and testified as follows:</p> <p>20 BY MS. SCULLION:</p> <p>21 Q. Good morning, Mr. Lortie.</p> <p>22 A. Good morning.</p> <p>23 Q. We met briefly off the record,</p> <p>24 but for the record, my name is Jennifer</p>
Page 11	Page 13
<p>1 EXHIBITS</p> <p>2 NO. DESCRIPTION PAGE</p> <p>3</p> <p>4 Endo- Lortie-34 File Provided Natively Slide deck, Opana ER Crush Resistant Formulation Research Wave 5, Qualitative Interviews, 12/13/12 [ENDO-CHI_LIT-001356] 368</p> <p>7</p> <p>8 Endo- Lortie-35 Endo Health Solutions Sues FDA to Protect Consumers from Non-Tamper Resistant Oxymorphone dated 11/30/12 [no Bates] 377</p> <p>12</p> <p>13 Endo- Lortie-36 File Provided Natively Compendia Status Update December 2012 [EPI001932419 and EPI002485011] 389</p> <p>15</p> <p>16 Endo- Lortie-37 E-mail string, top one dated 1/14/13 Subject, Re: generic OPANA ER [END00121820 through 1822] 399</p> <p>19</p> <p>20 Endo- Lortie-38 E-mail dated 1/12/13 Subject, Final Opana ER Strategic Platform with attachment provided natively [ENDO-CHI_LIT-00467546 through 7547] 403</p> <p>23</p> <p>24 ---</p>	<p>1 Scullion, and I represent the plaintiffs in this</p> <p>2 matter.</p> <p>3 Mr. Lortie, I'm going to hand you</p> <p>4 what's been marked as Exhibits 1 and 2.</p> <p>5 (Documents marked for</p> <p>6 identification as Endo-Lortie Deposition</p> <p>7 Exhibit Nos. 1 and 2.)</p> <p>8 BY MS. SCULLION:</p> <p>9 Q. Let me hand you Exhibit 1, which</p> <p>10 is a copy of the Notice of Deposition of Brian</p> <p>11 Lortie.</p> <p>12 A. Thank you.</p> <p>13 Q. And Exhibit 2 which is a copy of</p> <p>14 the subpoena.</p> <p>15 Mr. Lortie, before we look at the</p> <p>16 exhibits, have you ever been deposed before?</p> <p>17 A. Yes, I have.</p> <p>18 Q. How many times?</p> <p>19 A. I would have to think, but it's</p> <p>20 been several, probably five or six.</p> <p>21 Q. Were all of those in connection</p> <p>22 with your employment with Endo?</p> <p>23 A. The majority have been yes, some</p> <p>24 -- one or two with my prior employer.</p>

4 (Pages 10 to 13)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 14</p> <p>1 Q. And starting with the depositions 2 for Endo, can you tell me the subject matter of 3 the lawsuits that the depositions took place in? 4 A. Sure. To the best of my 5 recollection, they were either patent litigation 6 or there were two actual anti-trust cases, and 7 that's, I think, a complete record. 8 Q. My understanding is you did 9 testify before in an FTC proceeding. That was 10 an in court proceeding, right? 11 A. Correct, yes. 12 Q. Did you also testify in 13 deposition, or are you counting that as one of 14 the depositions I asked you about? 15 A. I'm counting that as one of the 16 depositions in front of the FTC, yes, yes. 17 Q. Okay. All right. And that 18 was -- that was the Impax matter, correct? 19 A. The FTC was involved in Impax and 20 I think it also involved Lidoderm as well, if 21 I'm recalling correctly. 22 Q. All right. Other than patent 23 litigations and anti-trust litigations, did you 24 testify in any other proceedings when you were</p>	<p style="text-align: right;">Page 16</p> <p>1 you well, but just so we can go over a couple of 2 ground rules for today. 3 Probably most important is that 4 we try to not speak over each other because Peg, 5 our court reporter, needs to be able to take 6 down our words, so I'm going to try to not speak 7 over your answers, if you could wait until I 8 finish my questions, and that way we can keep it 9 straight for the court reporter. 10 Does that work for you? 11 A. Sure. I will do my best. 12 Q. Thanks. The other thing is, 13 again, for the court reporter, we do need to 14 have actually oral responses, not shaking head 15 or uh-huh or uh-uhs. We need to actually put 16 words on the piece of paper. 17 Does that work for you? 18 A. Yes, I understand. 19 Q. Okay, great. And then if at any 20 point today you don't understand one of my 21 questions, would you please let me know? 22 A. Yes, I will. 23 Q. Thank you. Is there any reason 24 that you can't give your best testimony today?</p>
<p style="text-align: right;">Page 15</p> <p>1 with Endo? 2 A. No, I believe that's complete. 3 Q. Did you testify before the New 4 York Attorney General? 5 A. No, I did not. 6 Q. Did you submit written testimony 7 or declaration? 8 A. I don't recall. I may have. I'm 9 not sure. 10 Q. All right. And you said that 11 other than testimony with respect to your work 12 with Endo, you also testified for some prior 13 employers. Can you tell me about those? 14 A. Sure. GlaxoSmithKline was my 15 prior employer for the majority of my career. 16 There were two, I believe, depositions. One was 17 a patent case, intellectual property case, and 18 then quite a bit earlier I was a witness in an 19 employee relations age discrimination case, 20 again, with regards to my employment there. I 21 wasn't involved in the case. I was a deponent. 22 Q. So you've testified a number of 23 times, so I'm sure you're quite familiar with 24 the process, and counsel has, I'm sure, prepared</p>	<p style="text-align: right;">Page 17</p> <p>1 A. No, I don't think so. 2 Q. Not taking any medication that 3 would affect your cognitive abilities, for 4 example? 5 A. That's correct. 6 Q. That's correct that you're not 7 taking any? 8 A. It's correct I am not. 9 Q. Okay, thank you very much. 10 If you'll look at Exhibit Number 11 1, this is the Notice of Deposition of Brian 12 Lortie. 13 Are you aware that you are here 14 today to testify as a representative for Endo on 15 certain topics? 16 A. I am, yes. 17 Q. And are you aware you're also 18 here to testify today in your personal capacity? 19 A. Yes. 20 Q. Are you represented by counsel 21 today? 22 A. I am. 23 Q. Who is that? 24 A. Counsel to my left from Goodell,</p>

5 (Pages 14 to 17)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 18</p> <p>1 as well as Carrie Hazard from Endo. 2 Q. Okay. And can you just briefly 3 go over what I understand to be the topics that 4 you are to be representative on today, and I'll 5 ask you let me know if you understand these to 6 be the topics as well. 7 So the first topic -- 8 MR. LIMBACHER: Jen, I don't mean 9 to interrupt. 10 MS. SCULLION: No, please. 11 MR. LIMBACHER: Just for purposes 12 of the record, I think Endo has served 13 objections to the 30(b)(6) notice, and I 14 think there's also been considerable 15 correspondence back and forth between 16 counsel with regard to the scope of the 17 topics on which he has been designated. 18 So if there's any issues or concerns 19 there, I'm happy to discuss it with you, 20 but I think you know the basic scope on 21 which he is being presented as a 22 30(b)(6) witness. 23 MS. SCULLION: And I'd just like 24 to confirm it with the witness. I agree</p>	<p style="text-align: right;">Page 20</p> <p>1 seeing it in writing, so but, yes, that sounds 2 like number 9. 3 Q. And the next topic, which is 4 topic number 13, is the process for determining 5 the accuracy, completeness and legality of and 6 approval and implementation of any sales or 7 marketing information Endo made available to 8 medical professionals, patients or the public 9 concerning opioids or any of Endo's opioid 10 products in any format, including printed 11 materials, videos, websites, any in-person 12 messaging or detailing by sales representatives. 13 14 Do you understand that you're 15 going to be testifying as to that process, 16 generally? 17 A. Yes, yes. 18 MR. LIMBACHER: Jen, just so 19 we're clear on the record, he'll be 20 testifying consistent with and subject 21 to the objections that Endo has served 22 you with with regard to the 30(b)(6) 23 notice and also within the scope of what 24 we have identified as appropriate areas</p>
<p style="text-align: right;">Page 19</p> <p>1 with those statements. 2 BY MS. SCULLION: 3 Q. So the first topic is any 4 analysis of the effectiveness of Endo's sales or 5 marketing efforts, including any analysis of 6 return on investment in sales or marketing 7 activities related to Endo's opioid products. 8 Do you have an understanding that 9 you're testifying on those topics? 10 A. Yes. Is that -- I mean, I see 11 that the topics are listed by number here. Can 12 I also take a look at the subpoena, just so 13 I'm -- 14 Q. The subpoena is actually 15 different, and we will get to that. The 16 subpoena is directed to you in your personal 17 capacity. 18 A. Okay. 19 Q. And we will get to that. 20 What I just recited was 21 identified as topic number 9, and you said, yes, 22 you understand you're going to be testifying on 23 that topic? 24 A. Yes, I was just accustomed to</p>	<p style="text-align: right;">Page 21</p> <p>1 for testimony with regard to each of 2 these topics, and that's been set forth 3 in considerable e-mail between I believe 4 yourself and Josh Davis. 5 MS. SCULLION: And you'll let me 6 know, obviously, you'll make an 7 objection if you think it's outside the 8 scope. 9 BY MS. SCULLION: 10 Q. With respect, though, to the 11 claims in marketing information concerning 12 Endo's opioid products, do you also understand 13 that you are prepared to testify to certain 14 specific claims that we provided to counsel to 15 testify to just what was the support for those 16 claims? 17 A. Yes, I understand that. 18 Q. Okay. And we have a chart that 19 we've been provided with, and we can walk 20 through some of that. 21 The next two topics that are 22 quite similar, and they relate to the applicable 23 policies, procedures, records and systems for 24 abuse and diversion issues at Endo. And on that</p>


6 (Pages 18 to 21)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 22</p> <p>1 what we've agreed to is that you be prepared to</p> <p>2 testify to the substance of the reasons for any</p> <p>3 changes to those policies or procedures, the</p> <p>4 effectiveness of those policies or procedures.</p> <p>5 And then topic 32 also goes to</p> <p>6 the procedures, record systems, training</p> <p>7 policies for ensuring compliance with abuse and</p> <p>8 diversion laws and regulations and, again, the</p> <p>9 substance of any reasons for any changes to</p> <p>10 those and the effectiveness of compliance</p> <p>11 procedures.</p> <p>12 Do you understand you're</p> <p>13 testifying to those issues as well?</p> <p>14 MR. LIMBACHER: Let me just</p> <p>15 object, because I don't know that you</p> <p>16 accurately characterized Endo's position</p> <p>17 with regard to what he's actually going</p> <p>18 to be designated to testify on with</p> <p>19 regard to topics 30, 31 and 32. The</p> <p>20 general subject matter you have</p> <p>21 accurately described, but in terms of</p> <p>22 the specifics of what he's prepared to</p> <p>23 testify to, I believe you misstated, but</p> <p>24 having said that, you can answer the</p>	<p style="text-align: right;">Page 24</p> <p>1 Q. Right. Is it your understanding</p> <p>2 that a separate representative will be speaking</p> <p>3 to suspicious order monitoring procedures?</p> <p>4 A. Yes, that's my understanding.</p> <p>5 Q. Okay. That's my understanding as</p> <p>6 well, so good.</p> <p>7 And then topic 39 is any effort</p> <p>8 you made directly or through any third party to</p> <p>9 collaborate with one or more other</p> <p>10 pharmaceutical manufacturers or distributors</p> <p>11 concerning marketing, use, prescribing, sale,</p> <p>12 distribution or regulation of any one or the</p> <p>13 class of opioid products, including any</p> <p>14 collaborative lobbying efforts concerning any of</p> <p>15 the foregoing.</p> <p>16 And do you understand you're</p> <p>17 prepared to testify to that topic as well?</p> <p>18 A. I do.</p> <p>19 MS. SCULLION: Why don't we take</p> <p>20 a short break, because I do want to</p> <p>21 clarify off the record on topics 30 and</p> <p>22 32. I apologize.</p> <p>23 THE VIDEOGRAPHER: Off the</p> <p>24 record, 9:18 a.m.</p>
<p style="text-align: right;">Page 23</p> <p>1 question, as best you can.</p> <p>2 MS. SCULLION: Well, on that we</p> <p>3 probably should then take a break,</p> <p>4 because I'm reading from language from</p> <p>5 an e-mail I sent to Josh Davis and that</p> <p>6 he confirmed. So I do want to be sure</p> <p>7 that we are on the same page on that.</p> <p>8 So let's finish this, and then, I think,</p> <p>9 take a quick break because I do want to</p> <p>10 make sure that we're on the same page.</p> <p>11 BY MS. SCULLION:</p> <p>12 Q. You also would speak to the role</p> <p>13 of wholesalers, distributors and pharmacies in</p> <p>14 monitoring for abuse and diversion?</p> <p>15 A. Yes.</p> <p>16 MR. LIMBACHER: Topic 31.</p> <p>17 MS. SCULLION: Thirty-one, yes.</p> <p>18 THE WITNESS: Yes. And I believe</p> <p>19 there's a call out one exception to</p> <p>20 that, where another witness has been</p> <p>21 designated as corporate representative</p> <p>22 for one of the topics or one of the</p> <p>23 subtopics.</p> <p>24 BY MS. SCULLION:</p>	<p style="text-align: right;">Page 25</p> <p>1 (Brief recess.)</p> <p>2 THE VIDEOGRAPHER: We are back on</p> <p>3 the record at 9:37 a.m.</p> <p>4 MS. SCULLION: So we went off the</p> <p>5 record and had a discussion with</p> <p>6 Mr. Limbacher, and, Mr. Limbacher, will</p> <p>7 you confirm that my description of the</p> <p>8 topics for Mr. Lortie in 30 and 32 --</p> <p>9 30, 31 and 32 are accurate?</p> <p>10 MR. LIMBACHER: I believe that is</p> <p>11 consistent with the e-mail exchanges</p> <p>12 between Mr. Davis and yourself, but we</p> <p>13 stand by whatever is in those e-mails</p> <p>14 and, also, our objections to the</p> <p>15 30(b)(6) notice.</p> <p>16 MS. SCULLION: Okay. And it's</p> <p>17 our understanding that the objections</p> <p>18 have been addressed through the e-mail</p> <p>19 exchange. We won't burden the record</p> <p>20 further on that.</p> <p>21 BY MS. SCULLION:</p> <p>22 Q. Mr. Lortie, can you look at</p> <p>23 Exhibit Number 2, which is the subpoena?</p> <p>24 A. Yes.</p>

7 (Pages 22 to 25)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 26</p> <p>1 Q. Have you seen the subpoena 2 before? 3 A. Yes, I have. 4 Q. And do you understand it was 5 directed to you personally? 6 A. I do, yes. 7 Q. Okay. And the subpoena, if you 8 will turn to page 2, has categories of documents 9 that were requested. 10 Did you search your personal 11 records for these documents? 12 A. I don't have any personal records 13 with regards to this, but I was asked to confirm 14 that, yes. 15 Q. Okay. And that includes looking, 16 for example, at personal e-mails? 17 A. Correct. 18 Q. Okay. Terrific. We can put 19 aside Exhibit. 20 Number 2. 21 This morning we were handed a 22 copy of your CV. 23 Let me hand you a copy that's 24 been marked Exhibit Number 3.</p>	<p style="text-align: right;">Page 28</p> <p>1 has been spent in the pharmaceutical industry, 2 correct? 3 A. That is correct. 4 Q. And you started off at SmithKline 5 in 1987, and, as I read your resume, you joined 6 Endo in July of 2009; is that correct? 7 A. It's actually 1986. 8 Q. I'm so sorry. 9 A. Just to correct the record, when 10 I began with SmithKline, but you're correct, 11 2009 was when I joined Endo. 12 Q. Okay. And before joining Endo, 13 had you had any experience with marketing or 14 sales of controlled substances? 15 A. No. 16 Q. Did any of your prior -- any of 17 your work before Endo concern any pain products? 18 A. No, it did not. 19 Q. And at Endo, so you began in July 20 of 2009 as senior vice president and general 21 manager for branded pharmaceuticals. 22 And then you were promoted to 23 president for US branded pharmaceuticals in May 24 of 2014, correct?</p>
<p style="text-align: right;">Page 27</p> <p>1 (Document marked for 2 identification as Endo-Lortie Deposition 3 Exhibit No. 3.) 4 BY MS. SCULLION: 5 Q. Do you recognize Exhibit Number 6 3? 7 A. I do. 8 Q. And what is it? 9 A. It's a current copy of my resume. 10 Q. This is a resume you prepared? 11 A. It is. 12 Q. And, to the best of your 13 knowledge, it's accurate? 14 A. Yes. 15 Q. Okay. We can go back, start at 16 the beginning. As we were discussing off the 17 record, you have an undergraduate degree from BU 18 and that's a pre-med degree, correct? 19 A. It is correct, yes. 20 Q. And then you went on to Villanova 21 for business school? 22 A. I did, yes. 23 Q. And in terms of your employment 24 history, looks like the entirety of your career</p>	<p style="text-align: right;">Page 29</p> <p>1 A. That's correct. 2 Q. And then you were promoted again 3 to president and CEO -- I'm sorry, I got that 4 wrong entirely -- and then you left Endo in 5 October 2016, correct? 6 A. That is correct, yes. 7 Q. All right. Before we go back 8 into that, can we have Exhibit Number 4. 9 (Document marked for 10 identification as Endo-Lortie Deposition 11 Exhibit No. 4.) 12 BY MS. SCULLION: 13 Q. Hand you Exhibit Number 4 Bates 14 stamped ENDO_OPIOID_MDL_DEPONENT-000019346. 15 Do you recognize Exhibit Number 16  17 18 19 20 21 22 23 24</p>

8 (Pages 26 to 29)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 30</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 32</p> <p>1 [REDACTED]</p> <p>2 BY MS. SCULLION:</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 31</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 33</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 34</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 36</p> <p>1 I'd caution the witness not to 2 inadvertently disclose any privileged 3 communications, but you can go ahead and 4 answer the question. 5 THE WITNESS: No. All of my work 6 done has been in preparation for this 7 deposition with regards to this 8 litigation. 9 BY MS. SCULLION: 10 Q. And to make sure just more 11 broadly, since leaving Endo, have you been paid 12 for your time by Endo in connection with 13 anything other than this litigation? 14 A. Only other litigation, which we 15 described before, other depositions in the same 16 fashion. 17 Q. Okay. Do you have any -- other 18 than the Separation Agreement, which is Exhibit 19 4, do you have any other current agreements with 20 Endo? 21 A. I do not. 22 Q. Do you have any current financial 23 interest in Endo? 24 A. I still remain a shareholder, so</p>
<p style="text-align: right;">Page 35</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 Q. Okay. Other than preparing for 20 today's deposition and being here today as 21 Endo's corporate representative on certain 22 topics, have you provided any other cooperation 23 to Endo in connection with this litigation? 24 MR. LIMBACHER: Object to form.</p>	<p style="text-align: right;">Page 37</p> <p>1 I own some equity, but, other than that, no. 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 sure, I've asked a series of questions about 12 your relationships with Endo, do you have any 13 current relationship with Par, Par 14 Pharmaceuticals? 15 A. Not -- no. 16 Q. And do you have any -- so no 17 current agreements, correct? 18 A. That's correct. 19 Q. And no current financial 20 relationship with Par? 21 A. That's correct. 22 Q. Okay. Let's go back to your CV, 23 Exhibit Number 3, and focusing on your time at 24 Endo. It says here that you were -- on page 2</p>

10 (Pages 34 to 37)

Highly Confidential - Subject to Further Confidentiality Review

Page 38

1 that you were a member of the executive
2 leadership team.

3 What was that?

4 A. Yes, and, again, I should point
5 out just for accuracy, that period described
6 2009 through 2014, my job responsibilities
7 evolved over time, more things were added and at
8 the -- I would say around the middle of 2013, I
9 was named to the executive leadership team. The
10 executive leadership team was essentially the
11 senior leaders of the corporation, for the most
12 part, direct reports of the CEO. And there were
13 periods of time there where I was a direct
14 report. There were also some periods of time
15 there where there was a chief operating officer
16 that I reported to and that person reported to
17 the CEO.

18 Q. Do you know which period of time
19 you reported to a chief operating officer?

20 A. The first chief operating officer
21 I reported to in, if I recall correctly, March
22 of 2011, and I believe she left in May of 2013.
23 From May of 2013, if my recollection is correct,
24 until around August or September of 2013, I

Page 40

1 [REDACTED]
2 [REDACTED]
3 [REDACTED]
4 [REDACTED]
5 [REDACTED]
6 [REDACTED]
7 [REDACTED]
8 [REDACTED]
9 [REDACTED]
10 [REDACTED]

11 Q. During the time that you were
12 employed by Endo, I want to make sure I
13 understand, were you ever a member of the PMRB?

14 A. I was not a direct member of the
15 PRB, although those who were reporting to me or
16 reporting up through my business were sitting
17 members on that team.

18 Q. But you, yourself were not a
19 member of the PMRB?

20 A. I believe I was not directly
21 myself.

22 Q. And we'll talk a little bit in
23 more detail about PMRB in a bit, but, similarly,
24 you, yourself, were not a member of MARC,

Page 39

1 reported to the chief executive.

2 Then another chief operating
3 officer was recruited and I reported to him
4 until sometime in 2014, when he departed. I
5 don't recall the exact date.

6 And from that point forward until
7 the end of my employment with Endo, I reported
8 directly to the chief executive.

9 [REDACTED]
10 [REDACTED]
11 [REDACTED]
12 [REDACTED]
13 [REDACTED]
14 [REDACTED]
15 [REDACTED]
16 [REDACTED]
17 [REDACTED]
18 [REDACTED]
19 [REDACTED]
20 [REDACTED]
21 [REDACTED]
22 [REDACTED]
23 [REDACTED]
24 [REDACTED]

Page 41

1 correct?

2 A. Correct, same answer with regards
3 to MARC. MARC was really an evolution of PMRB.


4 [REDACTED]
5 [REDACTED]
6 [REDACTED]
7 [REDACTED]
8 [REDACTED]
9 [REDACTED]
10 [REDACTED]
11 [REDACTED]
12 [REDACTED]
13 [REDACTED]
14 [REDACTED]
15 [REDACTED]
16 [REDACTED]
17 [REDACTED]
18 [REDACTED]
19 [REDACTED]
20 [REDACTED]
21 [REDACTED]

22 Q. Okay. Did you ever sit on any
23 compliance committee at Endo?

24 MR. LIMBACHER: Object to form.


11 (Pages 38 to 41)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 42</p> <p>1 THE WITNESS: I'm -- I don't</p> <p>2 recall specifically. Of course, I was</p> <p>3 well involved with our compliance</p> <p>4 officer and familiar with the activities</p> <p>5 and the requirements of that, but</p> <p>6 whether or not I actually sat on a</p> <p>7 compliance committee, sitting here</p> <p>8 today, I don't recall.</p> <p>9 BY MS. SCULLION:</p> <p>10 </p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19 point of clarification in terms of the scope of</p> <p>20 your testimony as a corporate representative</p> <p>21 today, we've been speaking of Endo. There was a</p> <p>22 period of time when Qualitest was a subsidiary</p> <p>23 of Endo, correct?</p> <p>24 A. Yes.</p>	<p style="text-align: right;">Page 44</p> <p>1 or expansion of our generic business, they were</p> <p>2 put together.</p> <p>3 Q. Okay.</p> <p>4 MS. SCULLION: Can I have the</p> <p>5 open letter.</p> <p>6 MR. LIMBACHER: Jen, I assume</p> <p>7 we're going to handle this one the way</p> <p>8 we handled Kristin Vitanza's deposition.</p> <p>9 You will let us know on the record when</p> <p>10 you're going to be asking him questions</p> <p>11 in his capacity as a 30(b)(6) witness,</p> <p>12 and then when you finish those</p> <p>13 questions, you'll let us know that</p> <p>14 you've finished and to the extent</p> <p>15 there's any uncertainty, we will assume</p> <p>16 that he is being questioned in his</p> <p>17 capacity as a fact witness.</p> <p>18 MS. SCULLION: Yes.</p> <p>19 MR. LIMBACHER: Thank you.</p> <p>20 MS. SCULLION: Thank you.</p> <p>21 BY MS. SCULLION:</p> <p>22 Q. And if you ever have any</p> <p>23 questions during the day about what capacity I'm</p> <p>24 asking you questions in, please, again, just let</p>
<p style="text-align: right;">Page 43</p> <p>1 Q. And are you going to be speaking</p> <p>2 today about the policies and procedures at</p> <p>3 Qualitest with respect to abuse and diversion</p> <p>4 issues?</p> <p>5 MR. LIMBACHER: Object to form.</p> <p>6 THE WITNESS: I am most familiar</p> <p>7 and prepared extensively on those that</p> <p>8 pertain to the branded business, which</p> <p>9 was my area of responsibility, and the</p> <p>10 company involved Qualitest was actually</p> <p>11 the result of an acquisition, and there</p> <p>12 were some distinctions there and some --</p> <p>13 frankly some personnel that we were able</p> <p>14 to take advantage of, but I'm not</p> <p>15 specifically prepared to testify in</p> <p>16 depth to Qualitest's policies and</p> <p>17 procedures.</p> <p>18 BY MS. SCULLION:</p> <p>19 Q. Okay. And the Qualitest</p> <p>20 functions were eventually moved over to Par</p> <p>21 after the Par acquisition, correct?</p> <p>22 A. Yes, that's correct. Qualitest</p> <p>23 was a generic business, and so either as a</p> <p>24 stand-alone or when Par came in as an extension</p>	<p style="text-align: right;">Page 45</p> <p>1 me know.</p> <p>2 A. I will ask for clarification.</p> <p>3 Thank you.</p> <p>4 (Document marked for</p> <p>5 identification as Endo-Lortie Deposition</p> <p>6 Exhibit No. 5.)</p> <p>7 BY MS. SCULLION:</p> <p>8 Q. Let me hand you a copy what's</p> <p>9 marked as Exhibit Number 5, which is a document</p> <p>10 taken from Endo's website entitled "Endo's Open</p> <p>11 Letter on the Opioid Abuse Crisis."</p> <p>12 And, Mr. Lortie, if I can direct</p> <p>13 your attention to the second paragraph, which</p> <p>14 discusses, The US FDA has worked to balance</p> <p>15 access to pain care medications for appropriate</p> <p>16 patients while aggressively mitigating the risks</p> <p>17 of opioid abuse.</p> <p>18 And the next sentence "Endo</p> <p>19 supports these efforts and has taken parallel</p> <p>20 actions."</p> <p>21 Let me ask you this question: As</p> <p>22 Endo's corporate representative, are you</p> <p>23 familiar with the actions that Endo has taken,</p> <p>24 the parallel actions Endo has taken to mitigate</p>

12 (Pages 42 to 45)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 46</p> <p>1 the risks of opioid abuse?</p> <p>2 MR. LIMBACHER: Object to form.</p> <p>3 Take your time and review the document.</p> <p>4 THE WITNESS: Yeah, I just --</p> <p>5 this letter actually, I believe, came</p> <p>6 out after I left the company, but if I</p> <p>7 could just take a second just to read it</p> <p>8 for context.</p> <p>9 MS. SCULLION: Yes, please.</p> <p>10 THE WITNESS: Thank you.</p> <p>11 MR. LIMBACHER: And you're</p> <p>12 questioning him with regard to which</p> <p>13 topic?</p> <p>14 MS. SCULLION: I believe this</p> <p>15 would be topic at least 30, likely 32.</p> <p>16 Again, I think those two bleed together.</p> <p>17 (Witness reviews document.)</p> <p>18 THE WITNESS: Okay, thank you.</p> <p>19 I've had a chance to look it over.</p> <p>20 BY MS. SCULLION:</p> <p>21 Q. Terrific.</p> <p>22 MR. LIMBACHER: Sorry, Jen. Just</p> <p>23 note my objection to the extent the</p> <p>24 exhibit that you're questioning him</p>	<p style="text-align: right;">Page 48</p> <p>1 I understand he was not at the company,</p> <p>2 but he is here today as the corporate</p> <p>3 representative on those issues, but let</p> <p>4 me just ask you.</p> <p>5 BY MS. SCULLION:</p> <p>6 Q. Are you prepared today to testify</p> <p>7 as Endo's corporate representative with respect</p> <p>8 to the -- what's described here some of -- as</p> <p>9 the parallel actions Endo took to mitigate the</p> <p>10 risks of opioid abuse?</p> <p>11 MR. LIMBACHER: Well, he's</p> <p>12 prepared to testify consistent with the</p> <p>13 e-mail exchanges between counsel and</p> <p>14 subject to the objections to the</p> <p>15 30(b)(6) notice.</p> <p>16 BY MS. SCULLION:</p> <p>17 Q. Let me ask you, as Endo's</p> <p>18 corporate representative, did Endo voluntarily</p> <p>19 stop promoting opioid products to healthcare</p> <p>20 professionals as one aspect of mitigating of the</p> <p>21 risks of opioid abuse?</p> <p>22 MR. LIMBACHER: I'm going to</p> <p>23 object to that question as being beyond</p> <p>24 the scope of the topics on which he has</p>
<p style="text-align: right;">Page 47</p> <p>1 about I think goes beyond the scope of</p> <p>2 topics 30 and 32, but you can go ahead</p> <p>3 and ask your questions.</p> <p>4 MS. SCULLION: Well, we really do</p> <p>5 need to understand that, because this</p> <p>6 does speak to parallel actions to</p> <p>7 mitigate the risks of opioid abuse, and</p> <p>8 topic 30 does speak to policies and</p> <p>9 procedures to, among other things, halt</p> <p>10 abuse. So our understanding is this</p> <p>11 falls squarely within the scope of the</p> <p>12 topic.</p> <p>13 MR. LIMBACHER: It also goes on</p> <p>14 to talk about things like, for example,</p> <p>15 the voluntary withdrawal of Opana ER</p> <p>16 from the market, which I think is beyond</p> <p>17 the scope of the topics and also is</p> <p>18 beyond the time period in which he was</p> <p>19 an employee at the company.</p> <p>20 MS. SCULLION: I mean, to the</p> <p>21 extent that Endo has identified these</p> <p>22 actions as being actions to mitigate the</p> <p>23 risks of opioid abuse, again, I think</p> <p>24 they fall squarely within the topic, and</p>	<p style="text-align: right;">Page 49</p> <p>1 been designated and as agreed upon</p> <p>2 between counsel in e-mails, but he can</p> <p>3 go ahead and answer the question.</p> <p>4 </p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17 Q. So if I understand, you're not</p> <p>18 prepared to testify today as Endo's corporate</p> <p>19 representative to that particular action</p> <p>20 identified as an action Endo took to mitigate</p> <p>21 the risks of opioid abuse?</p> <p>22 MR. LIMBACHER: Again, I'm going</p> <p>23 to object to the question to the extent</p> <p>24 it's beyond the scope of the topics on</p>

13 (Pages 46 to 49)

Highly Confidential - Subject to Further Confidentiality Review

Page 50	Page 52
<p>1 which he's been designated, but you can 2 go ahead and answer the question. 3 THE WITNESS: I've prepared to 4 discuss the many things that Endo had in 5 place, not just from September 2016 6 onward but really back even predating my 7 arrival and able to discuss those things 8 in detail. Endo has always been 9 committed to taking whatever steps it 10 could to mitigate abuse, diversion, 11 improper prescribing, et cetera. 12 But to the specifics around the 13 decision to be permanently -- to 14 permanently stop promoting Opana ER as 15 referred to here, there's a limit to 16 which I can represent anything there 17 because it happened after I had 18 departed. 19 MS. SCULLION: I think we'll get 20 back to the preparation for being a 21 corporate rep, but just to make sure I 22 understand the lines being drawn here, 23 counsel, is it your position that steps 24 Endo took to mitigate the risks of</p>	<p>1 steps that Endo took to mitigate abuse, 2 how do those not fall squarely within 3 the scope of the topic? 4 MR. LIMBACHER: How does what? 5 I'm confused by what your question is of 6 me at this point in time. 7 MS. SCULLION: The question is 8 why he would not be prepared to speak 9 to -- as a corporate representative to 10 speak to Endo's actions taken to 11 mitigate the risks of opioid abuse. 12 MR. LIMBACHER: He is prepared to 13 testify about that. The point I've been 14 trying to make, counsel, is that I think 15 it's beyond the scope of the agreements 16 that have been entered into between 17 counsel that he's here to talk about 18 the -- what led up to the voluntary 19 withdrawal of the product after he left 20 the company. 21 MR. TOLIN: And, Jen, I'd add 22 topic 48 states your decisions to 23 discontinue original Opana ER and 24 withdraw reformulated Opana ER from the</p>
Page 51	Page 53
<p>1 opioid abuse are beyond the scope of the 2 topics here. 3 MR. LIMBACHER: No. My position 4 is that he's prepared to testify 5 consistent with the e-mail exchanges 6 that you entered into with Mr. Davis. 7 He's here to testify with regard to the 8 policies regarding diversion, and I 9 think that questions with regard to the 10 voluntary withdrawal, which postdate his 11 employment at the company, are outside 12 the scope of the topics on which he has 13 been designated. 14 MS. SCULLION: I apologize for 15 burdening the record, but are you saying 16 he is designated solely with respect to 17 the issue of diversion, because our 18 understanding is he was designated with 19 respect to both diversion and abuse? 20 MR. LIMBACHER: He's -- yes, he's 21 here to testify with regard to diversion 22 and abuse with regard to topic number 23 30, I believe. 24 MS. SCULLION: Correct. And so</p>	<p>1 market, it seems to me your specific 2 question with respect to this letter 3 would apply to topic 48 and not the 4 topics on which he was designated. 5 MS. SCULLION: So I disagree. I 6 mean, the topic you just read, Adam, is 7 specific to Opana ER. The topics 30 and 8 32 speak more generally to opioid 9 products, as does the open letter, which 10 goes beyond the withdrawal of Opana ER 11 to stop -- Endo voluntarily having 12 stopped promoting opioid products to 13 healthcare professionals as an action to 14 mitigate the risks of opioid abuse. 15 I don't want to burden the record 16 further. It is our position that this 17 is an area that Endo was obligated to 18 provide a corporate representative on. 19 We are prepared to take testimony on 20 these issues today, and whether we do it 21 during a break or otherwise, we'll need 22 to take this up with the special master. 23 MR. LIMBACHER: Well, he's 24 prepared to testify consistent with the</p>

Highly Confidential - Subject to Further Confidentiality Review

Page 54	Page 56
<p>1 e-mail exchanges between counsel on the</p> <p>2 processes that were in place to deal</p> <p>3 with suspected abuse or diversion</p> <p>4 consistent with the language of topic</p> <p>5 number 30 in your 30(b)(6) deposition</p> <p>6 notice.</p> <p>7 He's not prepared and there's</p> <p>8 nothing, I don't think, in the e-mail</p> <p>9 exchanges to suggest that he should be</p> <p>10 prepared to talk specifically about the</p> <p>11 topic number 48 in your deposition</p> <p>12 notice. That is not a topic on which he</p> <p>13 has been designated.</p> <p>14 MS. SCULLION: All right. We're</p> <p>15 going to have to do this on the record,</p> <p>16 I apologize. Topic 48 is about the</p> <p>17 withdrawal of Opana ER. The topics on</p> <p>18 which Mr. Lortie has been designated are</p> <p>19 with respect to abuse, mitigation of</p> <p>20 abuse, more generally, for opioid</p> <p>21 products, and he is, as per the e-mail,</p> <p>22 to be testifying to the substance of any</p> <p>23 changes in those policy and procedures</p> <p>24 and the reasons for those changes and</p>	<p>1 Q. So, Mr. Lortie, let me ask you,</p> <p>2 so we can shortcut, I think, this dispute.</p> <p>3 In Exhibit Number 5 in the second</p> <p>4 paragraph, Endo describes a number of what it</p> <p>5 calls parallel actions it has taken to mitigate</p> <p>6 the risks of opioid abuse. One is it says</p> <p>7 voluntarily stop promoting opioid products to</p> <p>8 healthcare professionals, correct? I'm just</p> <p>9 asking what it says.</p> <p>10 A. Yes, that's correct.</p> <p>11 Q. Okay. And it says it "eliminated</p> <p>12 the company's entire pain product sales force,"</p> <p>13 correct?</p> <p>14 A. That's what it says, correct.</p> <p>15 Q. It also does say, "Endo</p> <p>16 voluntarily withdrew Opana ER from the market,"</p> <p>17 correct?</p> <p>18 A. That's correct.</p> <p>19 Q. "Discontinued the research and</p> <p>20 development of new opioid products", correct?</p> <p>21 A. That's correct.</p> <p>22 Q. "And implemented additional</p> <p>23 anti-diversion measures," correct?</p> <p>24 A. Yes, correct.</p>
Page 55	Page 57
<p>1 the effectiveness of the policies and</p> <p>2 procedures.</p> <p>3 And it's evident here that Endo</p> <p>4 made a policy decision as part of its</p> <p>5 efforts to mitigate the risks of opioid</p> <p>6 abuse, a policy decision to stop</p> <p>7 promoting opioid products to healthcare</p> <p>8 professionals, and so I am entitled to a</p> <p>9 corporate representative on that issue.</p> <p>10 If he's not -- if Mr. Lortie is</p> <p>11 not prepared or has not been prepared to</p> <p>12 speak to that topic today, we will need</p> <p>13 to have a representative prepared to</p> <p>14 come back.</p> <p>15 MR. LIMBACHER: He's prepared to</p> <p>16 testify on topics 9, 13, 30, 31, 32 and</p> <p>17 39, consistent with the e-mail exchanges</p> <p>18 between counsel.</p> <p>19 He is not prepared to testify,</p> <p>20 for example, with regard to topic number</p> <p>21 48.</p> <p>22 MS. SCULLION: I think we're</p> <p>23 talking past each other.</p> <p>24 BY MS. SCULLION:</p>	<p>1 Q. "Including product serialization</p> <p>2 aimed at thwarting counterfeiting and theft to</p> <p>3 protect patient safety."</p> <p>4 Did I read that correctly?</p> <p>5 A. You did, you read all of those</p> <p>6 correctly, and, again, it's describing those as</p> <p>7 actions taken "since," I'm reading from the</p> <p>8 document here, "our new executive leadership</p> <p>9 team began working together in September 2016."</p> <p>10 So, yes, you read that correctly.</p> <p>11 Q. Are you prepared as Endo's</p> <p>12 corporate representative today to speak to any</p> <p>13 of those actions Endo took to mitigate the risks</p> <p>14 of opioid abuse?</p> <p>15 MR. LIMBACHER: Jen, he's</p> <p>16 prepared to testify consistent with what</p> <p>17 I've described now repeatedly. He's</p> <p>18 here to testify specifically with regard</p> <p>19 to topics 30, 31 and 32 as limited by</p> <p>20 the e-mail exchanges between counsel.</p> <p>21 To the extent Exhibit 5</p> <p>22 references issues and topics and conduct</p> <p>23 that falls outside the scope of the</p> <p>24 agreements that counsel have arrived at</p>

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 58</p> <p>1 with regard to topics 30, 31 and 32, he</p> <p>2 is not prepared to testify as to that.</p> <p>3 You can ask him questions, but</p> <p>4 that's beyond the scope of what was</p> <p>5 agreed to.</p> <p>6 BY MS. SCULLION:</p> <p>7 Q. So I'm just trying -- I'm trying</p> <p>8 to make sure I understand because counsel has</p> <p>9 not been clear about what is the difference</p> <p>10 between my understanding of the scope and his</p> <p>11 understanding, so I'm trying to understand what</p> <p>12 you are or are not prepared to testify to today.</p> <p>13 Let's take one particular example.</p> <p>14 Can you identify for me today</p> <p>15 what the additional anti-diversion measures are</p> <p>16 that are referenced in this second paragraph of</p> <p>17 Exhibit 5?</p> <p>18 MR. LIMBACHER: Object to form,</p> <p>19 object to the extent it's beyond the</p> <p>20 scope of topics on which he's</p> <p>21 designated, but go ahead and answer the</p> <p>22 question.</p> <p>23 THE WITNESS: And I'm just going</p> <p>24 to ask for clarification when you use</p>	<p style="text-align: right;">Page 60</p> <p>1 A. I am not, no.</p> <p>2 MR. LIMBACHER: I think that's</p> <p>3 outside the scope of what he was</p> <p>4 designated on.</p> <p>5 MS. SCULLION: Counsel, is it</p> <p>6 your position it's outside the scope</p> <p>7 because it's after September 2016? I'm</p> <p>8 not clear.</p> <p>9 MR. LIMBACHER: No, it's because</p> <p>10 it's outside the scope of what you and</p> <p>11 Mr. Davis agreed upon, which was for him</p> <p>12 to be prepared to testify with regard to</p> <p>13 the processes that were in place with</p> <p>14 regard to suspected abuse and diversion.</p> <p>15 So that's the basis for my objection.</p> <p>16 MS. SCULLION: Well, the topic</p> <p>17 also speaks to policies and processes</p> <p>18 with respect to halting diversion, and</p> <p>19 anti-diversion measures clearly would be</p> <p>20 halting diversion. So it is our</p> <p>21 position that this is square within the</p> <p>22 topic that we need a representative on.</p> <p>23 I understand, Mr. Lortie, you're not --</p> <p>24 you've not been prepared on that today.</p>
<p style="text-align: right;">Page 59</p> <p>1 the word "additional," because I don't</p> <p>2 see that in here. So are you referring</p> <p>3 to those that are described that you</p> <p>4 just read into the record and described</p> <p>5 after occurring -- sorry -- occurring</p> <p>6 after September 2016?</p> <p>7 BY MS. SCULLION:</p> <p>8 Q. I am asking about steps taken</p> <p>9 after September 2016, and if you'll look at the</p> <p>10 second line from the bottom of that paragraph,</p> <p>11 it indicates one of the things that happened</p> <p>12 after September 2016 was Endo implemented</p> <p>13 additional anti-diversion measures including</p> <p>14 product serialization, and we read that, rest of</p> <p>15 that sentence before.</p> <p>16 Are you prepared as Endo's</p> <p>17 corporate representative today to tell me what</p> <p>18 those additional anti-diversion measures were?</p> <p>19 MR. LIMBACHER: That were</p> <p>20 implemented after September of 2016?</p> <p>21 MS. SCULLION: That's correct.</p> <p>22 BY MS. SCULLION:</p> <p>23 Q. Are you prepared to testify to</p> <p>24 that today?</p>	<p style="text-align: right;">Page 61</p> <p>1 BY MS. SCULLION:</p> <p>2 Q. Do you -- are you prepared to</p> <p>3 speak to any policies Endo adopted after 2016</p> <p>4 with regard to product serialization as one</p> <p>5 anti-diversion measure?</p> <p>6 A. No, I'm not prepared for that,</p> <p>7 no. I thought actually that was your last</p> <p>8 question of me so...</p> <p>9 Q. Trying to be a specific as I can.</p> <p>10 A. I understand.</p> <p>11 Q. And just to be clear, are you</p> <p>12 able to speak to Endo's policy decision to</p> <p>13 voluntarily stop promoting opioid products to</p> <p>14 healthcare professionals as part of its</p> <p>15 anti-abuse efforts?</p> <p>16 MR. LIMBACHER: And note my</p> <p>17 objection as I believe that topic in</p> <p>18 that question is beyond the scope on</p> <p>19 which he has been designated.</p> <p>20 THE WITNESS: And I'm not</p> <p>21 prepared. Again, that happened after I</p> <p>22 departed the company.</p> <p>23 BY MS. SCULLION:</p> <p>24 Q. Okay. Let's go back to then I</p>

16 (Pages 58 to 61)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 62</p> <p>1 want to ask you what did you do to prepare today</p> <p>2 to testify as Endo's corporate representative on</p> <p>3 Endo's policies and procedures with respect to</p> <p>4 abuse and diversion, including efforts to ensure</p> <p>5 compliance with applicable laws and regulations?</p> <p>6 A. Sure. And, in fact, this is</p> <p>7 consistent with how I prepared for all of the</p> <p>8 topics I've been designated on.</p> <p>9 I spent five or six days working</p> <p>10 with counsel, reviewing documents. I spoke to</p> <p>11 two Endo employees to help refresh my</p> <p>12 recollection of certain specific policies,</p> <p>13 procedures or identify the way certain materials</p> <p>14 had been used so I -- and I had considerable</p> <p>15 homework each evening.</p> <p>16 So, you know, I did my best to</p> <p>17 bring myself back up to speed so that I could be</p> <p>18 helpful today.</p> <p>19 Q. Which were the Endo employees</p> <p>20 that you spoke with?</p> <p>21 A. We spoke with Kristin Vitanza</p> <p>22 and, also, Brian Munroe, M-u-n-r-o-e. I think</p> <p>23 that was the only two people we spoke with, if I</p> <p>24 recall.</p>	<p style="text-align: right;">Page 64</p> <p>1 A. Specifically, there was a series</p> <p>2 of patient profiles called clin cases, if I'm</p> <p>3 recalling correctly. I didn't recall how they</p> <p>4 had been used, and given, I believe, some of the</p> <p>5 claims that are in question came out of those, I</p> <p>6 wanted to make sure I understood with whom they</p> <p>7 had been used and in what form the claims had</p> <p>8 been.</p> <p>9 Q. And what did Ms. Vitanza tell you</p> <p>10 in that regard?</p> <p>11 A. She clarified that they had been</p> <p>12 used as educational material with physicians, so</p> <p>13 we considered them promotional materials, and,</p> <p>14 therefore, those claims were subject to all of</p> <p>15 the necessary safeguards to ensure that they</p> <p>16 were well supported by medical evidence, they</p> <p>17 had been cleared by our medical, legal and</p> <p>18 regulatory team.</p> <p>19 Q. Did you discuss any other</p> <p>20 promotional materials with Ms. Vitanza?</p> <p>21 A. No, those were the ones in</p> <p>22 question.</p> <p>23 Q. Did you discuss any other topics</p> <p>24 at all with Ms. Vitanza that inform your</p>
<p style="text-align: right;">Page 63</p> <p>1 Q. When did you speak with</p> <p>2 Ms. Vitanza?</p> <p>3 A. Yesterday.</p> <p>4 Q. Approximately how long?</p> <p>5 A. How long did we --</p> <p>6 Q. Speak.</p> <p>7 A. 15, 20 minutes.</p> <p>8 Q. Was that by phone or in person?</p> <p>9 A. By telephone.</p> <p>10 Q. And did Ms. Vitanza provide you</p> <p>11 with information that will inform your testimony</p> <p>12 today as Endo's corporate representative on any</p> <p>13 of the topics we discussed?</p> <p>14 A. Yes, she did.</p> <p>15 Q. What information did you obtain</p> <p>16 from Ms. Vitanza?</p> <p>17 A. I had some specific questions on</p> <p>18 certain pieces of material, promotional</p> <p>19 material. I needed some help in understanding</p> <p>20 and recalling how they had specifically been</p> <p>21 used and with whom. She was able to clarify</p> <p>22 that.</p> <p>23 Q. Which pieces of material did you</p> <p>24 speak about?</p>	<p style="text-align: right;">Page 65</p> <p>1 testimony today?</p> <p>2 A. No. She was able to answer my</p> <p>3 question.</p> <p>4 Q. Okay. And Mr. Munroe, what did</p> <p>5 you speak with him about?</p> <p>6 A. I asked him to refresh my</p> <p>7 recollection as to the activities specifically</p> <p>8 of the Pain Care Forum. This was relative to</p> <p>9 the topic number 39, I believe.</p> <p>10 Q. Did you only speak to him about</p> <p>11 the Pain Care Forum?</p> <p>12 A. Yes.</p> <p>13 Q. When did you speak with</p> <p>14 Mr. Munroe?</p> <p>15 A. That was also yesterday.</p> <p>16 Q. And was that by phone as well?</p> <p>17 A. Yes.</p> <p>18 Q. About how long on the phone?</p> <p>19 A. We were on the phone maybe 45</p> <p>20 minutes or so, I think.</p> <p>21 Q. And what specifically did you</p> <p>22 discuss with Mr. Munroe about the Pain Care</p> <p>23 Forum?</p> <p>24 A. To the extent it related to topic</p>

17 (Pages 62 to 65)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 66</p> <p>1 39, I wanted to understand the specifics of how 2 that group was organized, what were the 3 objectives of the group, who were the members to 4 the extent -- sorry, let me rephrase that. 5 To what extent was it formal or 6 informal, some of the history. I was familiar 7 with the concept of the Pain Care Forum, but in 8 order to prepare adequately, I wanted to get 9 some specifics from him. 10 Q. And what did he provide? What 11 did he tell you about the specifics you asked 12 about? 13 A. He reminded me that this was an 14 informal gathering of a number of stakeholders 15 in the -- that would be interested in the world 16 of pain medicine, policy, legislation, 17 manufacturers, patient representatives, et 18 cetera. 19 And, importantly, he reminded me 20 that it was informal, the agenda was open. 21 There were no positions taken by the Pain Care 22 Forum, et cetera. I wanted clarity on 23 specifically some of those topics, so he was 24 able to remind me of what they did.</p>	<p style="text-align: right;">Page 68</p> <p>1 would call in on a teleconference line, they 2 were not required to identify themselves, so 3 he -- the point he was making is this was an 4 open forum to anyone that may be on any number 5 of the various facets of the topic were invited 6 to listen in, call in. So, you know, some 7 manufacturers were there routinely. He 8 mentioned that Purdue was often represented, 9 and, in fact, that the -- but we didn't speak 10 about -- he didn't identify any other specific 11 industry attendees, because, again, that 12 attendance was something that was fluid. 13 Q. And did you speak with Mr. Munroe 14 about the relationship between the Pain Care 15 Forum and the American Pain Foundation? 16 A. Not specifically. 17 MS. SCULLION: I apologize. 18 We're having a technical difficulty. 19 Off the record. 20 THE VIDEOGRAPHER: Off the record 21 at 10:22. 22 (Brief recess.) 23 THE VIDEOGRAPHER: We are back on 24 the record at 10:37 a m.</p>
<p style="text-align: right;">Page 67</p> <p>1 Q. In terms of the -- you said it 2 was a forum for a number of stakeholders you 3 said including manufacturers. 4 Do you know what other 5 manufacturers other than Endo of opioid products 6 were part of that forum? 7 MR. LIMBACHER: Jen, just so 8 we're clear, I assume these questions 9 are questions he is being asked in his 10 capacity as a 30(b)(6) witness? 11 MS. SCULLION: That's fine. 12 THE WITNESS: So your question 13 again, please. 14 BY MS. SCULLION: 15 Q. Sure. Do you know which other 16 manufacturers other than Endo of opioid products 17 were members of the Pain Care Forum? 18 A. The way it was represented to me 19 is that the membership was evolving and dynamic. 20 People would participate in some of the 21 meetings, not participate in others; that 22 literally the agenda, as well as the 23 participation was open. So he specifically 24 indicated that to the extent that some people</p>	<p style="text-align: right;">Page 69</p> <p>1 BY MS. SCULLION: 2 Q. Welcome back, Mr. Lortie. You 3 understand you're still under oath, correct? 4 A. I do. 5 Q. Thank you. We were speaking 6 about your discussion with Mr. Munroe, and you 7 explained your discussion of the Pain Care 8 Forum. 9 Is there anything else that you 10 discussed with Mr. Munroe? 11 A. No, that was essentially it. 12 Q. Okay. And other than Ms. Vitanza 13 and Mr. Munroe, is there anyone else other than 14 counsel that you spoke with to prepare for your 15 deposition as Endo's corporate representative? 16 A. No. 17 Q. You said you spent five or six 18 days preparing for -- to be Endo's corporate 19 representative. 20 When was that? 21 A. It's all been in the month of 22 January. I can't remember. We started on the 23 12th or 13th perhaps, and I spent considerable 24 time last weekend, I can tell you that.</p>

18 (Pages 66 to 69)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 70</p> <p>1 Q. Okay. And as we go through</p> <p>2 today, I'll ask you whether you've reviewed</p> <p>3 certain documents in connection with your</p> <p>4 preparation, I think that's probably the most</p> <p>5 efficient way to do that.</p> <p>6 BY MS. SCULLION:</p> <p>7 Q. Other than looking at documents</p> <p>8 with counsel, you said you did some home study</p> <p>9 and speaking with Ms. Vitanza and Mr. Munroe, is</p> <p>10 there anything else that you did to prepare to</p> <p>11 testify as Endo's corporate representative</p> <p>12 today?</p> <p>13 A. No, that's the complete list of</p> <p>14 activities.</p> <p>15 Q. And then separate from preparing</p> <p>16 to be Endo's corporate representative, is there</p> <p>17 anything else that you did to prepare for</p> <p>18 today's deposition?</p> <p>19 A. No, same activities helped me</p> <p>20 prepare for both.</p> <p>21 Q. Did you discuss today's</p> <p>22 deposition with anyone other than counsel?</p> <p>23 A. No.</p> <p>24 Q. Have you discussed this</p>	<p style="text-align: right;">Page 72</p> <p>1 A. No, I'm not prepared to do that.</p> <p>2 MR. LIMBACHER: And I would</p> <p>3 object as being beyond the scope of the</p> <p>4 designations.</p> <p>5 MS. SCULLION: And we disagree</p> <p>6 with that.</p> <p>7 BY MS. SCULLION:</p> <p>8 Q. And then, similarly, are you</p> <p>9 prepared to testify as to what Endo's current</p> <p>10 anti-diversion policies are?</p> <p>11 MR. LIMBACHER: Same objection.</p> <p>12 THE WITNESS: I am not. I</p> <p>13 haven't been there for over two years,</p> <p>14 so I can testify as to the activities</p> <p>15 that were underway during my employment,</p> <p>16 but not after.</p> <p>17 MS. SCULLION: Okay. And, again,</p> <p>18 we disagree with the objection as to</p> <p>19 scope.</p> <p>20 We're going to move on. We think</p> <p>21 we've made our position clear that these topics</p> <p>22 do fall squarely within the agreed scope of the</p> <p>23 topic. I understand counsel has taken a</p> <p>24 different position. We will reserve our rights</p>
<p style="text-align: right;">Page 71</p> <p>1 litigation with anyone other than counsel?</p> <p>2 A. I have not, no.</p> <p>3 Q. Okay. And just so we can be</p> <p>4 clear and I think move on in terms of the scope</p> <p>5 of your preparation, can you just confirm for</p> <p>6 me, are you prepared today to speak as Endo's</p> <p>7 corporate representative on any of Endo's</p> <p>8 anti-abuse policies that postdate the time you</p> <p>9 worked with the company?</p> <p>10 MR. LIMBACHER: Jen, I think</p> <p>11 we've been over this. He is prepared to</p> <p>12 testify with regard to abuse and</p> <p>13 diversion on the topics on which he's</p> <p>14 been designated consistent with the</p> <p>15 e-mail exchanges between counsel.</p> <p>16 BY MS. SCULLION:</p> <p>17 Q. Right. I just want to confirm</p> <p>18 because there's been some discussion about</p> <p>19 things that happened after you left and things</p> <p>20 that happened before.</p> <p>21 Are you prepared, for example, to</p> <p>22 testify as Endo's corporate representative with</p> <p>23 respect to what Endo's current anti-abuse</p> <p>24 policies are?</p>	<p style="text-align: right;">Page 73</p> <p>1 on that issue.</p> <p>2 BY MS. SCULLION:</p> <p>3 Q. Going back to your personal</p> <p>4 capacity.</p> <p>5 A. Thank you for the clarification.</p> <p>6 Q. When I asked you about Endo's</p> <p>7 open letter, Exhibit 5, and the reference to</p> <p>8 Endo voluntarily stopping promoting opioid</p> <p>9 products to healthcare professionals as a means</p> <p>10 of mitigating the risk of opioid abuse, you</p> <p>11 began to discuss it sounds like steps along</p> <p>12 those lines that did take place while you were</p> <p>13 with Endo. You've mentioned, I think,</p> <p>14 ratcheting down on the promotion of opioid</p> <p>15 products.</p> <p>16 Can you tell me what -- were</p> <p>17 there any steps that Endo took while you were</p> <p>18 with Endo to limit promotion of opioid products</p> <p>19 as a means of mitigating opioid abuse?</p> <p>20 MR. LIMBACHER: Object to form.</p> <p>21 THE WITNESS: To be clear, there</p> <p>22 were a number of steps that Endo took to</p> <p>23 reduce promotion generally after I</p> <p>24 arrived, across all product categories,</p>

19 (Pages 70 to 73)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 74</p> <p>1 including opioids, but also, 2 importantly, including others. 3 I should also maybe point out 4 that for the majority of the time I was 5 there, promotion of the opioids was not, 6 to the best of my recollection, 7 anywheres near the most significant 8 recipient of promotional attention or 9 money. But, generally, for business 10 reasons, we, I would say over the arc of 11 my time there, ratcheted down 12 promotional spend as well as detailing 13 across all products. 14 And it's in that context that I 15 was mentioning that there were times, in 16 fact, with regards to Opana ER where we 17 stopped promoting it because we were 18 launching alternative non-opioid 19 products but products that required 20 attention of the sales force, so that 21 was kind of what I was trying to 22 explain. 23 BY MS. SCULLION: 24 Q. Can you tell me when did Endo</p>	<p style="text-align: right;">Page 76</p> <p>1 BY MS. SCULLION: 2 Q. What was the newly acquired 3 product? 4 A. This was a product called 5 Sumavel, S-u-m-a-v-e-l. It was an injectable 6 product for the treatment of migraine. 7 Q. And the decision to switch the 8 promotional efforts from Opana ER to focus more 9 on Sumavel, you said that was purely for 10 commercial reasons, correct? 11 A. Yes. 12 Q. It was not intended to mitigate 13 opioid abuse, correct? 14 A. That's my recollection. 15 (Document marked for 16 identification as Endo-Lortie Deposition 17 Exhibit No. 6.) 18 BY MS. SCULLION: 19 Q. Handing you what's been marked as 20 Exhibit Number 6. 21 MS. SCULLION: And, I'm sorry, 22 what is the E number on this one? 23 MS. KUBLY: 1588. 24 BY MS. SCULLION:</p>
<p style="text-align: right;">Page 75</p> <p>1 stop actively promoting Opana ER? 2 MR. LIMBACHER: Objection. 3 BY MS. SCULLION: 4 Q. You just referenced a point in 5 time? 6 MR. LIMBACHER: Object to form. 7 THE WITNESS: Sure. And, again, 8 just for clarification, they 9 obviously -- and this letter helps us 10 understand that they stopped permanently 11 at a period of time after 12 September 2016. 13 We had a period where Opana was 14 not actively being promoted, to the best 15 of my recollection, and that was most 16 likely sometime in 2014. I don't recall 17 the specific dates of stopping and 18 restarting, but there was a period of 19 time there where we were launching a 20 newly acquired product and we made the 21 business decision to have the sales 22 force focus on the launch of that, and 23 we took them off of Opana ER. 24</p>	<p style="text-align: right;">Page 77</p> <p>1 Q. It's marked E1588 on the top 2 right-hand corner. 3 Do you recognize Exhibit Number 4 6, Mr. Lortie? 5 A. No, I don't believe I've seen 6 this. 7 Q. Okay. So this was not -- 8 obviously not something you reviewed in 9 connection with your preparation for today's 10 deposition, correct? 11 A. I believe that's true. I don't 12 recognize it. 13 Q. Okay. I'll represent to you that 14 it is a copy of what's labeled as the Endo 15 independent director's report of October 2018. 16 Again, this is a document we retrieved from 17 Endo's website, publicly available document. 18 If you could turn to what's page 19 1 of the document at the bottom. 20 MR. LIMBACHER: Take your time 21 and review the document. 22 BY MS. SCULLION: 23 Q. I'm going to just point you to 24 specific parts of the document. If at any point</p>

Highly Confidential - Subject to Further Confidentiality Review


<p style="text-align: right;">Page 78</p> <p>1 you think you need to review more, you can let 2 me know. 3 A. Thank you. 4 Q. Just looking at the top under 5 "Introduction," you will see it refers to "Since 6 its founding as a family business in 1920, Endo 7 International plc ("we", "Endo" or the 8 "Company") has evolved into a generics and 9 specialty branded pharmaceutical company with an 10 innovative suite of branded and generic 11 medications helping millions of patients lead 12 healthier lives." 13 Did I read that correctly? 14 A. That's what it says here, yes. 15 Q. And if you look briefly back at 16 Exhibit Number 5, which was the open letter. 17 And you see that open letter 18 again starts off similarly, "Since its founding 19 as a family business in 1920, Endo has evolved 20 into a generics and specialty branded 21 pharmaceutical company whose products help 22 millions of patients lead healthier lives." 23 Did I read that correctly? 24 A. Yes, you did.</p>	<p style="text-align: right;">Page 80</p> <p>1 Q. Is your understanding, though, 2 that the Endo entity that was founded, as you 3 said, as a spin-off of DuPont Merck that it 4 acquired a portfolio of products, product rights 5 from DuPont Merck? 6 MR. LIMBACHER: Object to form 7 and foundation. 8 THE WITNESS: Yes, that's my 9 understanding. 10 BY MS. SCULLION: 11 Q. And among that portfolio, there 12 was Percocet; is that right? 13 A. Yes, that's correct, that's my 14 understanding. 15 Q. And are you familiar with 16 Numorphan? 17 A. Not specifically, no. 18 Q. Okay. Do you recall that among 19 the portfolio of product rights Endo acquired 20 from DuPont Merck were rights with respect to 21 oxymorphone products? 22 A. That I don't know in detail. As 23 you said, I recognize that Percocet and the 24 Percocet products were part of the -- were part</p>
<p style="text-align: right;">Page 79</p> <p>1 Q. When you were with Endo, did Endo 2 similarly promote its heritage going back to a 3 family business in 1920? 4 MR. LIMBACHER: Object to form. 5 THE WITNESS: No, it didn't. In 6 fact, I'm somewhat surprised to read 7 that because that's not consistent with 8 what my understanding was, but, no, we 9 didn't promote that as part of the 10 company message. 11 BY MS. SCULLION: 12 Q. Do you recall that there was a 13 business by the name of Endo that was founded 14 some decades prior to the Endo that you worked 15 for being founded? 16 A. Yes, and I am aware of that in 17 history, and my understanding was that that was 18 a completely separate entity, even though the 19 name was the same name and that the name was 20 readopted after the company was established in 21 1999 or 2000 as a spin out from DuPont Merck. 22 So my understanding was always that there was a 23 disconnection between the two, other than the 24 fact that they share a name.</p>	<p style="text-align: right;">Page 81</p> <p>1 of the management led buyout, but beyond that, I 2 don't know what the specific products were. 3 Q. Okay. And Percocet, do you 4 recall that's an oxycodone APAP combination 5 product? 6 A. Yes, I understand. 7 Q. So going back to this Exhibit 8 Number 6, the Independent Directors' Report, I'd 9 like to get a sense from this again of what 10 areas of Endo's risk mitigation you're prepared 11 to testify to. 12 If you look to page 2 of the 13 document, you'll see under the heading that says 14 "Recent Risk Mitigation Efforts," this section 15 appears to discuss the efforts since 16 September 2016, we've already discussed that at 17 some length about whether you're prepared to 18 testify as Endo's rep on that. 19 But let me take you to the top of 20 the next page, page 3. 21 MR. LIMBACHER: Jen, I'm a little 22 confused. I thought when you handed him 23 this document you said you were going to 24 be asking him questions in his capacity</p>

21 (Pages 78 to 81)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 82</p> <p>1 as a fact witness. Are we now asking</p> <p>2 him questions in his role as a 30(b)(6)</p> <p>3 witness?</p> <p>4 MS. SCULLION: You're right. I</p> <p>5 have switched back to the 30(b)(6).</p> <p>6 Thank you very much.</p> <p>7 BY MS. SCULLION:</p> <p>8 Q. So now we're back in 30(b)(6)</p> <p>9 land.</p> <p>10 A. Duly noted. Thank you.</p> <p>11 Q. Keep saying we thought about</p> <p>12 bringing actual hats, but that won't really work</p> <p>13 too well.</p> <p>14 So top of page 3, you see the</p> <p>15 reference in the last line of the carryover</p> <p>16 paragraph to "FDA's Risk Evaluation and</p> <p>17 Mitigation Strategy ("REMS") program"?</p> <p>18 A. This is little (v) in that top</p> <p>19 paragraph?</p> <p>20 Q. Yes.</p> <p>21 A. Yes, I see that.</p> <p>22 Q. At some point in time, Opana ER</p> <p>23 was subject to a class wide REMS, correct?</p> <p>24 A. That's correct, yes.</p>	<p style="text-align: right;">Page 84</p> <p>1 BY MS. SCULLION:</p> <p>2 Q. Okay. And then I think counsel</p> <p>3 is also referring to a document which we'll look</p> <p>4 at a little bit later, a RiskMAP.</p> <p>5 Do you recall that prior to --</p> <p>6 strike that.</p> <p>7 Do you recall that REMS was</p> <p>8 implemented for Opana ER as well as all of their</p> <p>9 long-acting opioids in I believe 2012; is that</p> <p>10 right?</p> <p>11 A. That's my understanding, yes.</p> <p>12 That was an industry wide program that was put</p> <p>13 into place that supplemented and followed but</p> <p>14 didn't replace the RiskMAP. RiskMAP had been in</p> <p>15 place since 2007.</p> <p>16 Q. Right. So you are prepared to</p> <p>17 speak today to RiskMAP for Opana ER?</p> <p>18 A. I am and I also -- as counsel</p> <p>19 pointed out, I have some of those documents in</p> <p>20 front of me, so we can discuss those.</p> <p>21 Q. Right.</p> <p>22 Are you prepared to speak to</p> <p>23 Endo's RiskMAP with respect to its generic</p> <p>24 OxyContin product?</p>
<p style="text-align: right;">Page 83</p> <p>1 Q. Are you prepared today to speak</p> <p>2 to the policies and procedures that Endo adopted</p> <p>3 to implement REMS with respect to Opana ER?</p> <p>4 MR. LIMBACHER: Just for the sake</p> <p>5 of the record, to the extent that that</p> <p>6 subject falls within the scope of the</p> <p>7 topics on which he has been designated</p> <p>8 consistent with e-mail correspondence</p> <p>9 between counsel, he is prepared to give</p> <p>10 that testimony.</p> <p>11 And I believe we identified for</p> <p>12 you yesterday some topics -- I'm</p> <p>13 sorry -- some documents that he was</p> <p>14 going to have in front of him, which, in</p> <p>15 fact, he does have in front of him,</p> <p>16 including, I think, the REMS document.</p> <p>17 THE WITNESS: Yes, that's my</p> <p>18 understanding. I will only say that I'm</p> <p>19 not aware of what Endo may have done</p> <p>20 since the time I left, so to the extent</p> <p>21 that there are changes to it I'm not</p> <p>22 aware of, I can't testify to those, but,</p> <p>23 generally speaking, the REMS program I'm</p> <p>24 prepared to testify on.</p>	<p style="text-align: right;">Page 85</p> <p>1 MR. LIMBACHER: Object to the</p> <p>2 form.</p> <p>3 THE WITNESS: I have not done</p> <p>4 that, no.</p> <p>5 MR. LIMBACHER: I'm not sure that</p> <p>6 falls within the scope of the topics on</p> <p>7 which he's designated.</p> <p>8 BY MS. SCULLION:</p> <p>9 Q. Did Endo -- do you recall that</p> <p>10 Endo did for a period of time in 2004, I think</p> <p>11 2004, 2006, sell a generic OxyContin --</p> <p>12 oxycodone product, rather?</p> <p>13 A. For two reasons, one being that</p> <p>14 that predated me by considerable time, and also</p> <p>15 if it was a generic, that would have been on the</p> <p>16 generic side of the business. I don't really</p> <p>17 have any particular information or knowledge on</p> <p>18 that topic.</p> <p>19 Q. Oxycodone is an opioid product,</p> <p>20 correct?</p> <p>21 A. Oxycodone is an opioid, yes.</p> <p>22 MS. SCULLION: Okay. Counsel,</p> <p>23 the topic was not limited to --</p> <p>24 certainly was not limited to the branded</p>

Highly Confidential - Subject to Further Confidentiality Review

Page 86	Page 88
<p>1 opioids. It's all opioid products.</p> <p>2 That product was sold by Endo, not by</p> <p>3 Qualitest, and we do need a corporate</p> <p>4 representative to speak to Endo's</p> <p>5 policies and procedures with respect to</p> <p>6 addressing risks of abuse and diversion</p> <p>7 with respect to generic OxyContin. I</p> <p>8 understand the witness is not prepared</p> <p>9 on that today. I'm not faulting him for</p> <p>10 that. I'm just pointing it out so we're</p> <p>11 going to reserve our rights on that.</p> <p>12 MR. LIMBACHER: I'm not sure it</p> <p>13 does fall within the scope of the topics</p> <p>14 on which he's been designated.</p> <p>15 MS. SCULLION: We'll take it up</p> <p>16 off the record. The special master made</p> <p>17 very clear this case involves the</p> <p>18 generics as well.</p> <p>19 MR. LIMBACHER: I'm not disputing</p> <p>20 that. The issue is what topics he's</p> <p>21 been designated on.</p> <p>22 BY MS. SCULLION:</p> <p>23 Q. If you'll go down to the bottom</p> <p>24 of that same page we were on, the last paragraph</p>	<p>1 MS. SCULLION: Okay. The reason</p> <p>2 I ask is that's not our understanding of</p> <p>3 what suspicious order monitoring</p> <p>4 entails, but that's fine, as long as</p> <p>5 there's going to be somebody to speak to</p> <p>6 that aspect of anti-diversion.</p> <p>7 BY MS. SCULLION:</p> <p>8 Q. Let's continue down in that same</p> <p>9 paragraph. The next to last sentence on this</p> <p>10 page begins "Endo's Pharmacovigilance."</p> <p>11 Do you see that?</p> <p>12 A. Yes, I see that.</p> <p>13 Q. Okay. And this speaks to</p> <p>14 pharmacovigilance and risk management reviewing</p> <p>15 adverse event reports received via postmarketing</p> <p>16 surveillance.</p> <p>17 Are you prepared today to speak</p> <p>18 to Endo's policies and procedures with respect</p> <p>19 to those reviews?</p> <p>20 MR. LIMBACHER: And, counsel,</p> <p>21 consistent with the e-mail exchanges</p> <p>22 you've had with Mr. Davis, he's prepared</p> <p>23 to testify with regard to the process of</p> <p>24 reviewing adverse event reports received</p>
Page 87	Page 89
<p>1 speaks to "the company" -- in this case Endo --</p> <p>2 "maintains programs for overseeing and tracking</p> <p>3 shipments for signals of potential diversion."</p> <p>4 Do you see that sentence or that</p> <p>5 portion of the first sentence?</p> <p>6 A. Yes, I see that.</p> <p>7 Q. Okay. Are you prepared today to</p> <p>8 speak to Endo's programs to oversee and track</p> <p>9 shipments for signals of potential diversion</p> <p>10 with respect to any opioid products?</p> <p>11 A. I believe this falls under the</p> <p>12 suspicious order management, so I am not</p> <p>13 prepared on that. I think we've got somebody</p> <p>14 else who is going to cover that.</p> <p>15 Q. Okay. That's one of the things I</p> <p>16 did want to clarify.</p> <p>17 MS. SCULLION: Counsel, is it</p> <p>18 Endo's intention to have those issues</p> <p>19 addressed by the representative</p> <p>20 designated for suspicious order</p> <p>21 monitoring.</p> <p>22 MR. LIMBACHER: Specific to</p> <p>23 overseeing and tracking shipments, I</p> <p>24 think the answer is yes.</p>	<p>1 postmarketing.</p> <p>2 MS. SCULLION: Terrific.</p> <p>3 BY MS. SCULLION:</p> <p>4 Q. Let me ask you this as Endo's</p> <p>5 corporate representative: The reference here to</p> <p>6 Endo's risk management department, do you know</p> <p>7 at what point in time a risk management</p> <p>8 department was established at Endo? Let me ask</p> <p>9 a better question.</p> <p>10 Do you know when a risk</p> <p>11 management department was established that had</p> <p>12 as part of its responsibilities reviewing</p> <p>13 adverse event reports via post-marketing</p> <p>14 surveillance?</p> <p>15 MR. LIMBACHER: And you're</p> <p>16 referencing the language at the bottom</p> <p>17 of page 3 that talks about Endo's</p> <p>18 pharmacovigilance and risk management</p> <p>19 department?</p> <p>20 MS. SCULLION: Good point. I had</p> <p>21 separated those.</p> <p>22 BY MS. SCULLION:</p> <p>23 </p> <p>24 </p>




23 (Pages 86 to 89)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 90</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p style="text-align: right;">Page 92</p> <p>1 A. I don't know the specific date.</p> <p>2 I know that there was a chief compliance officer</p> <p>3 in place when I joined in 2009, and there</p> <p>4 certainly was one there when I left in 2016.</p> <p>5 Q. Okay. Let's go down to the next</p> <p>6 paragraph, which speaks to Endo's robust</p> <p>7 compliance program operated by the compliance</p> <p>8 department has continued to evolve since its</p> <p>9 establishment in 2004.</p> <p>10 As Endo's corporate</p> <p>11 representative, are you prepared today to speak</p> <p>12 to what efforts, what compliance efforts were in</p> <p>13 place at Endo prior to 2004 with respect to</p> <p>14 opioid anti-abuse regulations and policies?</p> <p>15 MR. LIMBACHER: Object to form</p> <p>16 and object to the extent it's beyond the</p> <p>17 scope of the topics on which he has been</p> <p>18 designated.</p> <p>19 THE WITNESS: Specifically, I</p> <p>20 can't, I'm not prepared, I wasn't there.</p> <p>21 To the extent that they represent things</p> <p>22 that continued during my tenure, I can</p> <p>23 certainly speak to that, but I can't --</p> <p>24 I'm not prepared to speak about what</p>
<p style="text-align: right;">Page 91</p> <p>1 Q. If you'll go to the next page, 4,</p> <p>2 under the heading "Historical and Existing</p> <p>3 Compliance Measures."</p> <p>4 So a similar question to what we</p> <p>5 just talked about before, but the second</p> <p>6 paragraph, which refers to, in quotes,</p> <p>7 compliance department, Endo's Compliance and</p> <p>8 Business Practices Department, it says (the</p> <p>9 "Compliance Department").</p> <p>10 Do you know when Endo established</p> <p>11 that department?</p> <p>12 A. Endo had a compliance function,</p> <p>13 chief compliance officer reporting to the CEO as</p> <p>14 well as to the board during my entire career</p> <p>15 there.</p> <p>16 I don't recall specifically them</p> <p>17 calling it the compliance and business practices</p> <p>18 department, again, but the compliance function</p> <p>19 was fully staffed and an important function</p> <p>20 during all of my time there, and I assume it</p> <p>21 continues.</p> <p>22 Q. Do you know when before your time</p> <p>23 there a chief compliance officer position had</p> <p>24 been established?</p>	<p style="text-align: right;">Page 93</p> <p>1 happened prior to my arrival,</p> <p>2 specifically five years prior to my</p> <p>3 arrival here in this case.</p> <p>4 BY MS. SCULLION:</p> <p>5 Q. And I asked you that question</p> <p>6 with respect to compliance efforts for</p> <p>7 anti-abuse regulations.</p> <p>8 Is your answer the same with</p> <p>9 respect to compliance efforts for anti-diversion</p> <p>10 regulations and laws prior to 2004, are you</p> <p>11 prepared to speak to those?</p> <p>12 MR. LIMBACHER: Object to form</p> <p>13 and object to the extent it goes beyond</p> <p>14 the scope of the topics on which he's</p> <p>15 been designated.</p> <p>16 THE WITNESS: No, I am not</p> <p>17 prepared to address those topics.</p> <p>18 MS. SCULLION: Counsel, Endo had</p> <p>19 objected to time frame initially. That</p> <p>20 objection was resolved and the time</p> <p>21 frame objection was withdrawn, largely</p> <p>22 in response to the special master having</p> <p>23 ruled that the generics business and</p> <p>24 business other than just Opana ER was</p>

24 (Pages 90 to 93)

Highly Confidential - Subject to Further Confidentiality Review





<p style="text-align: right;">Page 94</p> <p>1 fairly part of this case and is</p> <p>2 relevant. So, again, I understand we</p> <p>3 may have a difference of opinion.</p> <p>4 Clearly, the witness is not prepared</p> <p>5 and, again not faulting him, but we're</p> <p>6 going to reserve our rights to seek</p> <p>7 additional testimony on that period.</p> <p>8 MR. LIMBACHER: I think he's</p> <p>9 prepared to testify with regard to the</p> <p>10 abuse and diversion policies in place</p> <p>11 that are reflected in the June of 2007</p> <p>12 RiskMAP, which would predate his</p> <p>13 employment at the company. I don't know</p> <p>14 that he's prepared to testify with</p> <p>15 regard to policies that predate 2004.</p> <p>16 MS. SCULLION: Right.</p> <p>17 BY MS. SCULLION:</p> <p>18 Q. You recall, though, that Endo was</p> <p>19 actively marketing, for example, Percocet prior</p> <p>20 to 2004?</p> <p>21 A. I'm not sure of the timing, but,</p> <p>22 again, you've already established that that was</p> <p>23 part of the company formation, so I think that</p> <p>24 that's fair to say. That was part of our, at</p>	<p style="text-align: right;">Page 96</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>
<p style="text-align: right;">Page 95</p> <p>1 that time, quite small generics business,</p> <p>2 separate from branded, and, of course, it</p> <p>3 predates me by five years.</p> <p>4 Q. Okay. Let's go to the next page,</p> <p>5 5, and I'm looking at the second full paragraph,</p> <p>6 it begins "in February of 2014," second sentence</p> <p>7 of that paragraph -- sorry, the paragraph is</p> <p>8 discussing the corporate integrity agreement,</p> <p>9 which we discussed earlier, correct?</p> <p>10 A. Yes, I see the paragraph.</p> <p>11 Q. Okay. And the second sentence</p> <p>12 says, "Pursuant to the CIA, Endo developed and</p> <p>13 implemented a Field Force Monitoring Program</p> <p>14 ("FFMP") to evaluate and monitor its sales</p> <p>15 representatives' interactions with HCPs."</p> <p>16 </p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 97</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

25 (Pages 94 to 97)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 98</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p style="text-align: right;">Page 100</p> <p>1 designation of this RAMP, that's not a -- that's</p> <p>2 not an acronym that I'm familiar with, so this</p> <p>3 may have come together in the period of time</p> <p>4 after I left.</p> <p>5 Having said that, I can certainly</p> <p>6 speak to activities related to promotional</p> <p>7 activities, risk assessment activities</p> <p>8 undertaken that I think is in here, but I can't</p> <p>9 attest to whether or not that's complete under</p> <p>10 this topic of RAMP because I don't recognize</p> <p>11 what RAMP -- the complete details of what RAMP</p> <p>12 may refer to.</p> <p>13 Q. Okay. If you go to the next</p> <p>14 page, 6, the heading "Review and approval of</p> <p>15 promotional materials," you see this first</p> <p>16 paragraph refers to the "Marketing and</p> <p>17 Advertising Review Committee ("MARC")"? </p> <p>18 A. Yes. Again, I'm going to just</p> <p>19 take a minute and read the paragraphs here just</p> <p>20 to orient myself.</p> <p>21 Q. Sure.</p> <p>22 A. (Witness reviews document.)</p> <p>23 Okay, I've read that section.</p> <p>24 Thank you.</p>
<p style="text-align: right;">Page 99</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 paragraphs down, the paragraph begins, "The</p> <p>6 compliance department has also implemented a</p> <p>7 risk assessment and mitigation process (RAMP) to</p> <p>8 standardize and centralize risk assessments</p> <p>9 relating to promotional activities."</p> <p>10 Are you prepared as Endo's</p> <p>11 corporate representative to speak to the RAMP</p> <p>12 process?</p> <p>13 MR. LIMBACHER: Object to the</p> <p>14 extent that that calls for him to</p> <p>15 testify beyond the scope of the topics</p> <p>16 on which he's been designated as</p> <p>17 described in more detail in the e-mails</p> <p>18 between counsel.</p> <p>19 MS. SCULLION: Again, we'll</p> <p>20 disagree that it's beyond the scope.</p> <p>21 BY MS. SCULLION:</p> <p>22 Q. Are you prepared to speak to</p> <p>23 that?</p> <p>24 A. Again, with regards to the</p>	<p style="text-align: right;">Page 101</p> <p>1 Q. Okay. And I think you explained</p> <p>2 earlier you're now prepared to testify to Endo's</p> <p>3 policies and procedures implemented through MARC</p> <p>4 with respect to opioid products, correct?</p> <p>5 A. Yes, I think I'm well prepared</p> <p>6 for that.</p> <p>7 Q. Okay. And to be clear, the</p> <p>8 predecessor to MARC was the PMRB, correct?</p> <p>9 A. Yes.</p> <p>10 Q. And you're prepared to testify to</p> <p>11 the policies and procedures used by the PMRB</p> <p>12 with respect to opioid products, correct?</p> <p>13 A. I believe they're essentially one</p> <p>14 in the same, to my recollection, so yes.</p> <p>15 Q. That's what we're going to get</p> <p>16 to.</p> <p>17 If you go to page 7, the heading</p> <p>18 "Identification of healthcare providers eligible</p> <p>19 for; sales calls."</p> <p>20 Do you see that heading?</p> <p>21 A. I do.</p> <p>22 Q. And then the second paragraph</p> <p>23 down, the second sentence says, "The company's</p> <p>24 Abuse and Diversion Detection Program ("ADD</p>

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 102</p> <p>1 program") has included," and then it lists a 2 number of items there. 3 Are you familiar with the 4 company's ADD program referenced here? 5 A. I am in general. Again, it's -- 6 I'm familiar with that acronym. It really -- 7 all of these link back to the RiskMAP, the REMS 8 in terms of policies and procedures the company 9 had in place for many years to accomplish the 10 objectives set out here and explained here. 11 Q. I think I misheard your 12 testimony, but you are not familiar with the ADD 13 -- 14 A. I'm familiar with that acronym. 15 Q. You are? 16 A. I am, yes. 17 Q. Okay, I heard wrong. Thank you. 18 A. Sorry, my mistake. 19 Q. No, no, I heard incorrectly. 20 Okay. And I think you said 21 you're prepared to speak to that today as Endo's 22 corporate representative, correct? 23 MR. LIMBACHER: To the extent 24 that it falls within the scope of the</p>	<p style="text-align: right;">Page 104</p> <p>1  2 3 4 5 6 Q. Got it. Thank you. 7 And then the last paragraph on 8 this page 7 does speak to suspicious order 9 monitoring programs, and I think we discussed 10 that there's going to be a separate corporate 11 representative on those issues. 12 But let's take off your corporate 13 representative hat then for the moment. Just 14 based on your experience at Endo, was there 15 any -- was there any connection between the ADD 16 program and the SOM programs at Endo? 17 MR. LIMBACHER: Object to form. 18 BY MS. SCULLION: 19  20 21 22 23 24</p>
<p style="text-align: right;">Page 103</p> <p>1 topics on which he's been designated, 2 yes, he's prepared. 3 MS. SCULLION: Okay. 4 THE WITNESS: Just for clarity, 5 within the documents here that I have to 6 refer to in real time, we have the 7 RiskMAP and the REMS. I don't think we 8 have the ADD document specifically, so 9 it may be that I need some help, but if 10 you've got some specific point in that, 11 something that I can refer to, but, 12 generally, I'm prepared to address that 13 topic. 14 BY MS. SCULLION: 15  16 17 18 19 20 21 22 23 24</p>	<p style="text-align: right;">Page 105</p> <p>1  2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p>

27 (Pages 102 to 105)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 106</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p style="text-align: right;">Page 108</p> <p>1 for the entirety of time that Endo sold opioid</p> <p>2 products?</p> <p>3 MR. LIMBACHER: Object to the</p> <p>4 extent it falls outside the scope of the</p> <p>5 topics on which he's been designated.</p> <p>6 MS. SCULLION: Again, we disagree</p> <p>7 with that.</p> <p>8 THE WITNESS: Well, as explained</p> <p>9 here, this is discussing the</p> <p>10 establishment in 2004, which I wasn't</p> <p>11 aware of for an earlier question, and it</p> <p>12 explains that the compliance department</p> <p>13 and the policies and procedures have</p> <p>14 continued to evolve since that point in</p> <p>15 time.</p> <p>16 With regards to Opana, which was</p> <p>17 launched in 2006 or Opana ER -- sorry --</p> <p>18 Opana ER and Opana, I believe, were both</p> <p>19 launched in 2006 and my arrival in 2009,</p> <p>20 this is consistent with my recollection</p> <p>21 for that period of time. Prior to that,</p> <p>22 I can't attest to what happened.</p> <p>23 BY MS. SCULLION:</p> <p>24 Q. Okay. So --</p>
<p style="text-align: right;">Page 107</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 Q. One more thing, in that same</p> <p>13 exhibit, the independent director's report, turn</p> <p>14 to page 4, Exhibit Number 6 again.</p> <p>15 Bottom of page 4, the last</p> <p>16 paragraph, last sentence says, "Endo's</p> <p>17 compliance program incorporates the fundamental</p> <p>18 elements of an effective compliance program</p> <p>19 including," and then there are bullet points at</p> <p>20 the bottom of page 4 that extend over to the top</p> <p>21 of page 5. I'm asking this in your capacity as</p> <p>22 Endo's corporate representative, were these</p> <p>23 fundamental elements of an effective compliance</p> <p>24 program applicable to Endo's compliance program</p>	<p style="text-align: right;">Page 109</p> <p>1 A. Or what the policies and</p> <p>2 procedures were.</p> <p>3 Q. Okay. So you'd agree that with</p> <p>4 respect to compliance -- sorry.</p> <p>5 With respect to enforcing, for</p> <p>6 example, the regulations and laws and policies</p> <p>7 for anti-abuse for opioids, that these</p> <p>8 fundamental elements of an effective compliance</p> <p>9 program would apply to such compliance efforts,</p> <p>10 correct?</p> <p>11 MR. LIMBACHER: Object to form.</p> <p>12 THE WITNESS: I'm really sorry, I</p> <p>13 really don't understand that question.</p> <p>14 BY MS. SCULLION:</p> <p>15 Q. Sure, try that one again.</p> <p>16 A. Yeah.</p> <p>17 Q. Well, you're here to speak today</p> <p>18 in part as Endo's corporate representative on</p> <p>19 Endo's efforts to ensure compliance with</p> <p>20 anti-abuse laws, regulations and policies,</p> <p>21 correct?</p> <p>22 MR. LIMBACHER: Object to form.</p> <p>23 THE WITNESS: To the extent that</p> <p>24 it's in the topics designated, yes.</p>

28 (Pages 106 to 109)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 110</p> <p>1 BY MS. SCULLION:</p> <p>2 Q. Okay. And same thing with</p> <p>3 respect to anti-diversion laws, regulations and</p> <p>4 policies, you're here to speak to Endo's</p> <p>5 compliance efforts with -- to ensure compliance</p> <p>6 with those laws, regulations and policies,</p> <p>7 right?</p> <p>8 MR. LIMBACHER: Object to form.</p> <p>9 THE WITNESS: Yeah, with the</p> <p>10 exception of specific detail on SOMS,</p> <p>11 that's my understanding.</p> <p>12 BY MS. SCULLION:</p> <p>13 Q. Correct, thank you.</p> <p>14 And you'd agree that for those</p> <p>15 compliance efforts to be effective, they would</p> <p>16 need to, for example, have as indicated in the</p> <p>17 first bullet point here, clear rules, clear set</p> <p>18 of rules?</p> <p>19 MR. LIMBACHER: Object to form.</p> <p>20 THE WITNESS: That sounds</p> <p>21 reasonable.</p> <p>22 BY MS. SCULLION:</p> <p>23 Q. Written down somewhere?</p> <p>24 A. I would think so.</p>	<p style="text-align: right;">Page 112</p> <p>1 Q. We talked about training and</p> <p>2 assessing the effectiveness of the training,</p> <p>3 also reasonable?</p> <p>4 MR. LIMBACHER: Object to form.</p> <p>5 THE WITNESS: I think that's</p> <p>6 reasonable.</p> <p>7 BY MS. SCULLION:</p> <p>8 Q. Keeping records so they could be</p> <p>9 subject to audit, correct?</p> <p>10 A. Again, sounds reasonable.</p> <p>11 Q. To then actually go in and audit</p> <p>12 records of compliance, that would also be a</p> <p>13 reasonable part of a compliance program?</p> <p>14 MR. LIMBACHER: Object to form.</p> <p>15 THE WITNESS: Probably have less</p> <p>16 particular knowledge about audit</p> <p>17 procedures as they -- as they pertain to</p> <p>18 compliance in general, so I'm not -- I'm</p> <p>19 less sure about that specifically. I</p> <p>20 know that under a CIA, for example,</p> <p>21 there are explicit rules and audit</p> <p>22 reporting. I'm not sure -- you're kind</p> <p>23 of describing a general concept for good</p> <p>24 compliance. So, you know, in that</p>
<p style="text-align: right;">Page 111</p> <p>1 Q. Okay. And there needs to be</p> <p>2 training on those rules and efforts to assess</p> <p>3 the effectiveness of those rules --</p> <p>4 MR. LIMBACHER: Object to form.</p> <p>5 BY MS. SCULLION:</p> <p>6 Q. -- effectiveness of the training?</p> <p>7 MR. LIMBACHER: Object to form.</p> <p>8 THE WITNESS: That sounds like a</p> <p>9 reasonable, reasonable statement.</p> <p>10 BY MS. SCULLION:</p> <p>11 Q. There should be records kept of</p> <p>12 the compliance process, correct?</p> <p>13 A. I think you're asking me just to</p> <p>14 explain what a rigorous compliance program would</p> <p>15 be. In my experience, during my time there, as</p> <p>16 well as at other companies, those things that</p> <p>17 you're mentioning sound like reasonable aspects</p> <p>18 of a typical compliance program.</p> <p>19 Q. Let's just make sure then that</p> <p>20 we're on the same page on that.</p> <p>21 So we said clear rules, yes,</p> <p>22 written down, yes, correct?</p> <p>23 A. I would think that would be</p> <p>24 reasonable, yes.</p>	<p style="text-align: right;">Page 113</p> <p>1 context, I'm not sure about the audit</p> <p>2 requirements or what would or would not</p> <p>3 be reasonable. I'm not an audit</p> <p>4 professional, for example.</p> <p>5 BY MS. SCULLION:</p> <p>6 Q. Okay. Would you agree that</p> <p>7 consistent discipline measures to ensure</p> <p>8 compliance would be a part of a reasonable</p> <p>9 compliance program?</p> <p>10 MR. LIMBACHER: Object to form.</p> <p>11 THE WITNESS: I would agree with</p> <p>12 that, yes.</p> <p>13 BY MS. SCULLION:</p> <p>14 Q. How about what's called tone at</p> <p>15 the top. Are you familiar with that phrase?</p> <p>16 A. Generally I've heard that, yes.</p> <p>17 Q. Okay. Well, let's look on page 4</p> <p>18 of Exhibit 6. If you look at the last bullet</p> <p>19 point there it says, "Effective lines of</p> <p>20 communication including messages from senior</p> <p>21 level leaders regarding commitment to</p> <p>22 compliance."</p> <p>23 Is messages from senior level</p> <p>24 leaders regarding commitment to compliance, is</p>

29 (Pages 110 to 113)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 114</p> <p>1 that's what referred to as tone at the top?</p> <p>2 MR. LIMBACHER: Object to form.</p> <p>3 THE WITNESS: I think that's</p> <p>4 consistent with my understanding of the</p> <p>5 term, yes.</p> <p>6 BY MS. SCULLION:</p> <p>7 Q. Okay. Would you agree it would</p> <p>8 be inconsistent with a reasonable compliance</p> <p>9 program if the tone at the top was that an</p> <p>10 anti-abuse policy was, quote, unquote, window</p> <p>11 dressing?</p> <p>12 MR. LIMBACHER: Object to form.</p> <p>13 THE WITNESS: Would I agree that</p> <p>14 it would be inconsistent and did you say</p> <p>15 that a senior leader would be the person</p> <p>16 writing or communicating?</p> <p>17 BY MS. SCULLION:</p> <p>18 Q. I'm sorry, that a senior leader</p> <p>19 would -- would, yeah, refer to an anti-abuse</p> <p>20 program as window dressing.</p> <p>21 MR. LIMBACHER: Object to form.</p> <p>22 THE WITNESS: It would be most</p> <p>23 helpful if there was a specific instance</p> <p>24 of communication so that I could</p>	<p style="text-align: right;">Page 116</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p style="text-align: right;">Page 115</p> <p>1 understand the context of the person,</p> <p>2 how we are describing senior leader.</p> <p>3 With those qualifications, in my</p> <p>4 opinion, yes, that would be correct,</p> <p>5 that that would be inconsistent with</p> <p>6 tone from the top.</p> <p>7 BY MS. SCULLION:</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p style="text-align: right;">Page 117</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 Q. Okay. And with regard to Endo's</p> <p>7 approach to ensuring compliance with -- let's</p> <p>8 start with compliance with the laws and</p> <p>9 regulations governing promotional materials --</p> <p>10 A. I'm sorry. I coughed literally</p> <p>11 when you said an important word. So before you</p> <p>12 say the whole thing, could you start again.</p> <p>13 Q. Absolutely.</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 118</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 120</p> <p>1 MS. SCULLION: Thank you, okay.</p> <p>2 BY MS. SCULLION:</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 119</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 MS. SCULLION: And just to be</p> <p>14 clear, I disagree with the scope</p> <p>15 objections.</p> <p>16 Counsel, if we can have an</p> <p>17 agreement that I don't need to keep</p> <p>18 saying that?</p> <p>19 MR. LIMBACHER: Yes, I agree you</p> <p>20 do not.</p> <p>21 MS. SCULLION: Assume I don't</p> <p>22 necessarily agree with your scope</p> <p>23 objections.</p> <p>24 MR. LIMBACHER: I understand.</p>	<p>Page 121</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

31 (Pages 118 to 121)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 122</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 124</p> <p>1 Do you recognize Exhibit Number 2 7? 3 A. Yes, I do. 4 Q. And is this a copy of the 5 June 2007 RiskMAP for Opana ER? 6 A. It is, yes. 7 Q. And this is one of the documents 8 that you did review to prepare for today's 9 deposition, correct? 10 A. That is correct. 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>
<p style="text-align: right;">Page 123</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 the RiskMAP. 15 (Document marked for 16 identification as Endo-Lortie Deposition 17 Exhibit No. 7.) 18 BY MS. SCULLION: 19 Q. Hand you what's been marked as 20 Exhibit Number 7, and Exhibit 7 is Bates stamped 21 ENDO-CHI_LIT-00234542. 22 Mr. Lortie, do you recognize -- 23 we'll go back to your personal capacity for the 24 moment.</p>	<p style="text-align: right;">Page 125</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>

32 (Pages 122 to 125)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 126</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 128</p> <p>1 some source of -- some inappropriate source of</p> <p>2 acquiring controlled substances for the purpose</p> <p>3 of using them outside of their intended medical</p> <p>4 use. So, for example, a physician's office who</p> <p>5 was prescribing said medicines for purposes</p> <p>6 other than their intended labeled use.</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 127</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 129</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 130</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 132</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 131</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 133</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

34 (Pages 130 to 133)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 134</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 136</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 135</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 137</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

35 (Pages 134 to 137)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 138</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 BY MS. SCULLION: 20 Q. Right, so but you're not prepared 21 to testify today -- 22 A. That's correct. 23 Q. -- as Endo's corporate 24 representative with respect to Endo's policies</p>	<p style="text-align: right;">Page 140</p> <p>1 MR. LIMBACHER: Object to form 2 and object to the extent it falls 3 outside of the scope of the topics on 4 which he has been designated. 5 THE WITNESS: Yeah, I think 6 specifically by definition what you're 7 asking is the suspicious order 8 monitoring program because that defines 9 what the distribution center has, so I 10 believe you have another witness that 11 will represent the company on that topic 12 or that portion of the topic. 13 BY MS. SCULLION: 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>
<p style="text-align: right;">Page 139</p> <p>1 about ensuring against diversion at its 2 contracted -- sorry, contractual manufacturers, 3 correct? 4 A. Specifically, I think you're 5 correct. 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 BY MS. SCULLION: 20 Q. Okay. And are you able to speak 21 today to Endo's policies with respect to 22 ensuring that its contracted distribution center 23 had sufficient anti-diversion procedures in 24 place?</p>	<p style="text-align: right;">Page 141</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>

36 (Pages 138 to 141)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 142</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 144</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 143</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 145</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

37 (Pages 142 to 145)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 146</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 148</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 147</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 149</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

38 (Pages 146 to 149)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 150</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 152</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 151</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 153</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

39 (Pages 150 to 153)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 154</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 156</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 155</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 (Document marked for</p> <p>6 identification as Endo-Lortie Deposition</p> <p>7 Exhibit No. 8.)</p> <p>8 BY MS. SCULLION:</p> <p>9 Q. Hand you what's been marked as</p> <p>10 Exhibit Number 8. Exhibit Number 8 is Bates</p> <p>11 stamped ENDO-OPIOID_MDL-00869053, and we've</p> <p>12 marked it in the upper right-hand corner, E1175.</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 157</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

40 (Pages 154 to 157)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 158</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 BY MS. SCULLION:</p> <p>16 Q. Are you aware of anyone -- put</p> <p>17 your corporate representative hat back on.</p> <p>18 A. Okay.</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 160</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 159</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 161</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

41 (Pages 158 to 161)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 162</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 164</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 163</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 165</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

42 (Pages 162 to 165)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 166</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 168</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 167</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 169</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 MS. SCULLION: Okay. We can stop</p> <p>21 here for lunch.</p> <p>22 MR. LIMBACHER: Thank you.</p> <p>23 THE VIDEOGRAPHER: Going off the</p> <p>24 record at 12:38 p.m.</p>


43 (Pages 166 to 169)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 170</p> <p>1 (Luncheon recess.)</p> <p>2 THE VIDEOGRAPHER: We are back on</p> <p>3 the record at 1:19.</p> <p>4 BY MS. SCULLION:</p> <p>5 Q. Welcome back, Mr. Lortie. You</p> <p>6 understand you're still under oath, correct?</p> <p>7 A. Of course, yes.</p> <p>8 Q. Thank you.</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>Page 172</p> <p>1</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>
<p>Page 171</p> <p>1</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>Page 173</p> <p>1</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8 Q. Okay. And to be clear, all these</p> <p>9 questions are in your 30(b)(6) capacity?</p> <p>10 A. Okay.</p> <p>11 Q. Or representative capacity.</p> <p>12 And let me hand you what's been</p> <p>13 marked as Exhibit 9.</p> <p>14 (Document marked for</p> <p>15 identification as Endo-Lortie</p> <p>16 Deposition Exhibit No. 9.)</p> <p>17 BY MS. SCULLION:</p> <p>18 Q. I'll hand you what's been marked</p> <p>19 as Exhibit Number 9. And Exhibit Number 9 is</p> <p>20 Bates stamped ENDO-OPIOID_MDL-02924490, and we</p> <p>21 have stamped it in the upper right-hand corner</p> <p>22 E1247.</p> <p>23 And, Mr. Lortie, if you could</p> <p>24 turn to page E1247.5, which is the last of the</p>

44 (Pages 170 to 173)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 174</p> <p>1 ordinary size, eight and a half by 11 size 2 pages? 3 A. Okay. 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 176</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 
<p>Page 175</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 177</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 

45 (Pages 174 to 177)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 178</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 180</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 179</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 181</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

46 (Pages 178 to 181)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 182</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 184</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 183</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 185</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

47 (Pages 182 to 185)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 186</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 188</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 187</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 189</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

48 (Pages 186 to 189)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 190</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 192</p> <p>1 30(b)(6).</p> <p>2 MR. LIMBACHER: I'm sorry?</p> <p>3 MS. SCULLION: These are</p> <p>4 30(b)(6).</p> <p>5 MR. LIMBACHER: I object to the</p> <p>6 extent they fall outside the scope of</p> <p>7 the topics on which he has been</p> <p>8 designated.</p> <p>9 (Document marked for</p> <p>10 identification as Endo-Lortie Deposition</p> <p>11 Exhibit No. 11.)</p> <p>12 BY MS. SCULLION:</p> <p>13 Q. Mr. Lortie, let me hand you</p> <p>14 Exhibit Number 11, and that is Bates stamped</p> <p>15 ENDO-OR-CID-00408959. Upper right-hand corner</p> <p>16 we've marked it E1599.</p> <p>17 And --</p> <p>18 A. I'll just take a look, if it's</p> <p>19 okay.</p> <p>20 Q. Sure.</p> <p>21 A. (Witness reviews document.)</p> <p>22 Thank you. I've looked it over.</p> <p>23 Q. You've looked over Exhibit Number</p> <p>24 11.</p>
<p>Page 191</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 MR. LIMBACHER: Object to form,</p> <p>13 objection to the extent this falls</p> <p>14 outside the scope of the topics on which</p> <p>15 he's been designated.</p> <p>16 THE WITNESS: Yeah, I'm not sure</p> <p>17 I understand your question. Sorry.</p> <p>18 MS. SCULLION: Sure. Let's look</p> <p>19 at some documents. Can I have E1599,</p> <p>20 1600 and 1601.</p> <p>21 MR. LIMBACHER: Are these</p> <p>22 questions in his capacity as a fact</p> <p>23 witness or as a 30(b)(6) witness?</p> <p>24 MS. SCULLION: These are</p>	<p>Page 193</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>





49 (Pages 190 to 193)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 194</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 196</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 195</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 197</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 (Document marked for</p> <p>20 identification as Endo-Lortie Deposition</p> <p>21 Exhibit No. 12.)</p> <p>22 BY MS. SCULLION:</p> <p>23 Q. Okay. Hand you what's been</p> <p>24 marked Exhibit Number 12, and Number 12 is Bates</p>

50 (Pages 194 to 197)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 198</p> <p>1 stamped ENDO-OPIOID_MDL-02098725, and we've</p> <p>2 stamped it E1600.1.</p> <p>3 </p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11 Do you see that?</p> <p>12 MR. LIMBACHER: Object to form.</p> <p>13 THE WITNESS: So what's the -- I</p> <p>14 mean, I see the two forms that you're</p> <p>15 referring to, yes.</p> <p>16 BY MS. SCULLION:</p> <p>17 Q. Okay. And this is a prelude then</p> <p>18 to the next document. I just want to make sure</p> <p>19 you saw the chain of events here.</p> <p>20 And then let's look at Exhibit</p> <p>21 Number 13.</p> <p>22 (Document marked for</p> <p>23 identification as Endo-Lortie Deposition</p> <p>24 Exhibit No. 13.)</p>	<p style="text-align: right;">Page 200</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>
<p style="text-align: right;">Page 199</p> <p>1 THE WITNESS: Let me just finish</p> <p>2 with this one.</p> <p>3 MS. SCULLION: Sure.</p> <p>4 THE WITNESS: I'll take that, but</p> <p>5 I'm going to look at it in a second.</p> <p>6 (Witness reviews document.)</p> <p>7 MS. SCULLION: And for the</p> <p>8 record, Exhibit Number 13 is Bates</p> <p>9 stamped ENDO-OPIOID_MDL-02182533.</p> <p>10 MR. LIMBACHER: Again, note my</p> <p>11 objection to this series of questions to</p> <p>12 the extent it falls outside the scope of</p> <p>13 the topics on which he's been</p> <p>14 designated.</p> <p>15 BY MS. SCULLION:</p> <p>16 </p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 201</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

51 (Pages 198 to 201)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 202</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 204</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 203</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 205</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

52 (Pages 202 to 205)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 206</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 208</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 207</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 209</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

53 (Pages 206 to 209)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 210</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 212</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 211</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 213</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

54 (Pages 210 to 213)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 214</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 216</p> <p>1 stamped ENDO-CHI_LIT-00543478, and we've stamped 2 it in the upper right-hand corner E142. 3 Mr. Lortie, this is a document 4 entitled "Percocet History, Time & Events in the 5 News Media." It bears Endo's logo and it says 6 on the front it's prepared by Dhaval Mavani and 7 Jacob Gettier. 8 Do you know who those individuals 9 were? 10 A. I do not. No, I don't recognize 11 either of those names. I'll just take a look, 12 if it's okay through the slides. 13 Q. Yeah, sure. 14 A. (Witness reviews document.) 15 MR. LIMBACHER: Jen, when this 16 was produced, did it have the 17 handwriting on it? 18 MS. SCULLION: Yes, I checked 19 multiple times. It actually looked 20 suspiciously like mine, but it's not. 21 THE WITNESS: (Witness reviews 22 document.) 23 Okay. I mean, I've generally 24 looked at it. If there's a particular</p>
<p style="text-align: right;">Page 215</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 MS. SCULLION: Can I have E142, 15 478 and 1007, please. 16 MR. LIMBACHER: Jen, are we still 17 asking questions as a 30(b)(6) witness? 18 MS. SCULLION: Yes. 19 (Document marked for 20 identification as Endo-Lortie Deposition 21 Exhibit No. 14.) 22 BY MS. SCULLION: 23 Q. I hand you what's been marked as 24 Exhibit Number 14, and Exhibit 14 is Bates</p>	<p style="text-align: right;">Page 217</p> <p>1 page, I'm sure you'll point me to it. 2 BY MS. SCULLION: 3 Q. Sure. Yeah, if you can go to 4 E142.7. 5 You see the box in the middle of 6 the page there that says by 2002: approximately 7 9.7 million individuals age 12 and up had used 8 Percocet, Percodan or Tylox for nonmedical use 9 at least once in their life compared to 10 1.9 million for OxyContin. 11 Do you see that? 12 A. Yes, I do. 13 Q. Any reason to dispute those 14 numbers? 15 A. I have no reason to agree with 16 them nor dispute them. I have not seen this 17 before. It predates me by a long time and has 18 to do with Percocet, which wasn't subject of my 19 preparation today. 20 Q. Okay. And you'll see that that 21 box it says a source to the National Survey on 22 Drug Use and Health Report, May 2004. 23 It's at the bottom of the -- of 24 page E142.7.</p>

55 (Pages 214 to 217)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 218</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 (Document marked for 22 identification as Endo-Lortie Deposition 23 Exhibit No. 16.) 24 BY MS. SCULLION:</p>	<p style="text-align: right;">Page 220</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 outside the scope of the topics on which 7 he has been designated. 8 THE WITNESS: This document 9 predates my time there by at least eight 10 years, so I have no basis to understand 11 what Endo took into account at that 12 time. 13 BY MS. SCULLION: 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>
<p style="text-align: right;">Page 219</p> <p>1 Q. Let me hand you what's been 2 marked as Exhibit 16. And Exhibit 16 -- 3 MR. LIMBACHER: Is there a 15? 4 MS. SCULLION: There will be. 5 BY MS. SCULLION: 6 Q. Exhibit 16 is Bates stamped 7 ENDO-OPIOID_MDL-03259246, and we've marked it 8 E478 in the upper right-hand corner. 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 221</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 identification as Endo-Lortie Deposition 15 Exhibit No. 15.) 16 BY MS. SCULLION: 17 Q. Let me hand you now what's been 18 marked as Exhibit Number 15. 19 Exhibit 15 is an article from 20 Cleveland.com -- or it's just an opinion piece 21 rather from Cleveland.com authored by Carole 22 Rendon, and we've stamped it E1007.1, and it's 23 dated July 13th, 2016. 24 And if you'll go to page E1007.2,</p>

56 (Pages 218 to 221)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 222</p> <p>1 Ms. Rendon states four paragraphs down, "The</p> <p>2 opioid epidemic has caused an unprecedented wave</p> <p>3 of death and destruction throughout Northeast</p> <p>4 Ohio."</p> <p>5 Did I read that correctly?</p> <p>6 A. I'd like to look at the document</p> <p>7 first, if that's okay, quickly just to...</p> <p>8 Q. Sure.</p> <p>9 MR. LIMBACHER: Counsel, are we</p> <p>10 asking questions with regard to this</p> <p>11 document in his capacity as a 30(b)(6)</p> <p>12 witness?</p> <p>13 MS. SCULLION: We are.</p> <p>14 MR. LIMBACHER: Then I would</p> <p>15 object to all such questions as falling</p> <p>16 outside the scope of the topics on which</p> <p>17 he's been designated.</p> <p>18</p> <p>19 THE WITNESS: (Witness reviews</p> <p>20 document.)</p> <p>21 Okay. Thank you. I've taken a</p> <p>22 look.</p> <p>23 BY MS. SCULLION:</p> <p>24 [REDACTED]</p>	<p>Page 224</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 223</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 225</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>


57 (Pages 222 to 225)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 226</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 228</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 227</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 MR. LIMBACHER: Object to form.</p> <p>10 THE WITNESS: I'm sorry. I</p> <p>11 didn't hear the question.</p> <p>12 BY MS. SCULLION:</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 229</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

58 (Pages 226 to 229)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 230</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8 about an hour. Is this a good spot for</p> <p>9 a break?</p> <p>10 BY MS. SCULLION:</p> <p>11 Q. Do you know who Ms. Rendon is?</p> <p>12 A. Not other than what I read here</p> <p>13 on the paper.</p> <p>14 Q. At the time she was the U.S.</p> <p>15 Attorney for the Northern District of Ohio,</p> <p>16 correct?</p> <p>17 A. That's what this says, yes.</p> <p>18 Q. Are you aware that she is today</p> <p>19 Endo's counsel in this case?</p> <p>20 MR. LIMBACHER: Object to form.</p> <p>21 THE WITNESS: I'm not aware of</p> <p>22 that, no.</p> <p>23 MS. SCULLION: We can take a</p> <p>24 break.</p>	<p style="text-align: right;">Page 232</p> <p>1 My understanding is, for reasons</p> <p>2 I don't fully understand, you want to</p> <p>3 shut it down today at 5:30, and I would</p> <p>4 strongly encourage you to agree to let's</p> <p>5 go beyond 5:30, let's go until 7:00. I</p> <p>6 think that's a reasonable time for</p> <p>7 everybody, and that will make it much</p> <p>8 more likely that we're going to be able</p> <p>9 to complete the deposition tomorrow by a</p> <p>10 reasonable hour.</p> <p>11 MS. SCULLION: And as we also</p> <p>12 discussed off the record and in some</p> <p>13 prior e-mails, first we do appreciate</p> <p>14 the witness' ability to come back</p> <p>15 tomorrow beginning at 2:30. We had</p> <p>16 noticed the deposition to go day to day,</p> <p>17 and we had specifically given a heads-up</p> <p>18 a few weeks ago that we did expect your</p> <p>19 deposition to go for two days, given the</p> <p>20 breadth of the topics on which you're</p> <p>21 designated, as well as our intent to ask</p> <p>22 you questions in your personal capacity.</p> <p>23 And with that, although in cases</p> <p>24 where we only expected to have a</p>
<p style="text-align: right;">Page 231</p> <p>1 THE VIDEOGRAPHER: Off the</p> <p>2 record, 2:23.</p> <p>3 (Brief recess.)</p> <p>4 THE VIDEOGRAPHER: The time is</p> <p>5 now 2:39 p.m. We are back on the</p> <p>6 record.</p> <p>7 MR. LIMBACHER: Jen, I just</p> <p>8 wanted to put on the record, you and I</p> <p>9 talked briefly during the break with</p> <p>10 regard to how late we might go today and</p> <p>11 what we anticipate for tomorrow.</p> <p>12 My understanding is that you do</p> <p>13 not think you're going to be able to</p> <p>14 finish your questioning today. The</p> <p>15 witness is available to come back</p> <p>16 tomorrow. He can be here, he believes,</p> <p>17 and ready to go starting at 2:30. My</p> <p>18 preference, as I indicated during the</p> <p>19 break, is that we go tonight until a</p> <p>20 reasonable hour, approximately 7:00 to</p> <p>21 try to get as much done today so that</p> <p>22 tomorrow can be relatively brief, and we</p> <p>23 can complete the deposition as quickly</p> <p>24 as possible.</p>	<p style="text-align: right;">Page 233</p> <p>1 deposition for one day, we've been</p> <p>2 willing to go what I would call these</p> <p>3 marathon depositions until late in the</p> <p>4 evening. There's really just -- there's</p> <p>5 no need. We did give the heads-up. We</p> <p>6 give it for a reason. We planned for</p> <p>7 the two days.</p> <p>8 I was only given notice, I</p> <p>9 apologize, last night or yesterday, I</p> <p>10 should say, probably yesterday afternoon</p> <p>11 that you would not be available tomorrow</p> <p>12 morning but only in the afternoon.</p> <p>13 Nonetheless, we had planned for</p> <p>14 two days, and you can correct me if I'm</p> <p>15 wrong, but my understanding is that when</p> <p>16 there have been depositions going for</p> <p>17 two days planned in this case, that the</p> <p>18 practice has been to stop at around 5:30</p> <p>19 or 6:00 and then continue the next day.</p> <p>20 That's our intent. We intend to use,</p> <p>21 you know, our full-time, we're trying to</p> <p>22 be efficient about it.</p> <p>23 I will say that our disagreements</p> <p>24 as to the scope, in particular, have</p>

59 (Pages 230 to 233)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 234</p> <p>1 caused us to have to rejigger our</p> <p>2 approach to the examination, so that's</p> <p>3 also problematic for us, but we will go</p> <p>4 till 6:00 today, and then we can</p> <p>5 reconvene tomorrow.</p> <p>6 The witness did indicate, and I</p> <p>7 very much appreciate it, that he is able</p> <p>8 to then sit for as long as it takes, I</p> <p>9 think you said, tomorrow. We don't</p> <p>10 intend to go till 10:00 or 11:00 at</p> <p>11 night. And so if we get to a point</p> <p>12 tomorrow where we still have questions</p> <p>13 that we need to take -- examine you on</p> <p>14 and have not used our time and it's</p> <p>15 getting too late, we will just reconvene</p> <p>16 for another day.</p> <p>17 MR. LIMBACHER: Well, if you</p> <p>18 think you're going to need two full days</p> <p>19 with this witness, all the more reason,</p> <p>20 if we're going to resume tomorrow at</p> <p>21 2:30, that we should go later than 5:30</p> <p>22 today. I'm not sure I understand what</p> <p>23 the thinking is as to why you're so</p> <p>24 unwilling to make full use of the time</p>	<p style="text-align: right;">Page 236</p> <p>1 and a 30(b)(6) witness in one day.</p> <p>2 MS. SCULLION: And that hasn't</p> <p>3 happened always. For example, I think</p> <p>4 Dr. Shusterman, you know, was two days,</p> <p>5 also 30(b)(6) and a fact witness, and I</p> <p>6 think -- again, I think the first day</p> <p>7 was ended at 5:30 or 6:00 or so.</p> <p>8 MR. LIMBACHER: Just would point</p> <p>9 out that Mr. Lortie doesn't work for the</p> <p>10 company anymore and to try to have this</p> <p>11 deposition extend into a third day is</p> <p>12 really unreasonable. Under the</p> <p>13 circumstances, we should go well beyond</p> <p>14 5:30 today to try to get this finished</p> <p>15 tomorrow.</p> <p>16 MS. SCULLION: And, again, we're</p> <p>17 not trying to be unreasonable. We</p> <p>18 hadn't known that you weren't available</p> <p>19 tomorrow morning until we were told that</p> <p>20 yesterday. We had asked for you for two</p> <p>21 days. So, again, let's deal with it if</p> <p>22 the issue is still live at the end of</p> <p>23 tomorrow.</p> <p>24 (Document marked for</p>
<p style="text-align: right;">Page 235</p> <p>1 today. If we shut it down at 5:30, I'm</p> <p>2 not even sure we're going to have had a</p> <p>3 total of seven hours of questioning</p> <p>4 today.</p> <p>5 So, again, I would ask that we go</p> <p>6 past 5:30, we go past 6:00, we get as</p> <p>7 much done today as we can so that</p> <p>8 realistically we can get it finished</p> <p>9 tomorrow because I'm not interested and</p> <p>10 I don't think we're obligated to bring</p> <p>11 him back for a third day.</p> <p>12 MS. SCULLION: So I don't think</p> <p>13 we need to spend more time on this. We</p> <p>14 do think that we are entitled to the two</p> <p>15 full days. Again, we hadn't known he</p> <p>16 wasn't going to be available in the</p> <p>17 morning. We had given a heads-up that</p> <p>18 we wanted him for two full days. We can</p> <p>19 discuss this if and when it becomes an</p> <p>20 issue.</p> <p>21 MR. LIMBACHER: I'll just note</p> <p>22 from my experience that Kristin Vitanza</p> <p>23 was a 30(b)(6) witness as well, and we</p> <p>24 finished her up as both a fact witness</p>	<p style="text-align: right;">Page 237</p> <p>1 identification as Endo-Lortie Deposition</p> <p>2 Exhibit No. 17.)</p> <p>3 BY MS. SCULLION:</p> <p>4 Q. Let me hand you what's been</p> <p>5 marked as Exhibit Number 17. And Exhibit 17 is</p> <p>6 Bates stamped ENDO-OPIOID_MDL-01056072, and</p> <p>7 we've stamped it in the upper right-hand corner</p> <p>8 E1010.</p> <p>9 And, Mr. Lortie, asking you in</p> <p>10 your capacity -- these questions would be in</p> <p>11 your capacity as a corporate representative on</p> <p>12 the role of wholesalers and distributors and</p> <p>13 retailers in combating abuse and diversion of</p> <p>14 opioid products.</p> <p>15 So if you'll look at Exhibit 17,</p> <p>16 it's a series of e-mails attaching a McKesson</p> <p>17 distribution agreement and various amendments</p> <p>18 thereto. I'm not going to be asking you to go</p> <p>19 through the entirety of these contracts. And if</p> <p>20 I can direct your attention, though, to page in</p> <p>21 the upper right-hand corner E1010.10?</p> <p>22 A. 1010.10.</p> <p>23 Q. You got it.</p> <p>24 [REDACTED]</p>

60 (Pages 234 to 237)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 238</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 2.3 refers to "Chargeback Processing."</p> <p>16 Do you see that?</p> <p>17 A. Yes, I see that. I see that vi.</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 240</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 239</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 241</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

61 (Pages 238 to 241)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 242</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 244</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 243</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 245</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

62 (Pages 242 to 245)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 246</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 248</p> <p>1 concerning promotional materials.</p> <p>2 A. Okay.</p> <p>3 Q. That's one of the areas in which</p> <p>4 you have been designated, correct?</p> <p>5 A. Yes.</p> <p>6 Q. Okay.</p> <p>7 MS. SCULLION: Could we have</p> <p>8 exhibits 1458 and 1456.</p> <p>9 (Document marked for</p> <p>10 identification as Endo-Lortie Deposition</p> <p>11 Exhibit No. 18.)</p> <p>12 BY MS. SCULLION:</p> <p>13 Q. I'll hand you what's been marked</p> <p>14 as Exhibit Number 18. I'm going to need a copy.</p> <p>15 And Exhibit 18 is Bates stamped</p> <p>16 END00747325, and we have marked it in the upper</p> <p>17 right-hand corner E1458.</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 247</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 Q. Okay. Do you recall whether at</p> <p>21 any point in time -- strike that.</p> <p>22 I'd like to ask you some</p> <p>23 questions with respect to Endo's policies and</p> <p>24 procedures for enforcing laws and regulations</p>	<p>Page 249</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 Q. Okay. You did review this in --</p> <p>5 A. I did.</p> <p>6 Q. -- the course of preparing for</p> <p>7 today's deposition? Okay.</p> <p>8 MS. SCULLION: And then can we</p> <p>9 have 1456.</p> <p>10 (Document marked for</p> <p>11 identification as Endo-Lortie Deposition</p> <p>12 Exhibit No. 19.)</p> <p>13 BY MS. SCULLION:</p> <p>14 Q. Now I'm going to hand you what's</p> <p>15 been marked as Exhibit 19.</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

63 (Pages 246 to 249)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 250</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 252</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 251</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 253</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

64 (Pages 250 to 253)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 254</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 MR. LIMBACHER: Are you asking</p> <p>11 these questions in his capacity as a</p> <p>12 30(b)(6) witness?</p> <p>13 MS. SCULLION: I am, because one</p> <p>14 of the aspects of the 30(b)(6) is with</p> <p>15 respect to compliance as it applied to</p> <p>16 enforcement of abuse and diversion laws</p> <p>17 and regulations.</p> <p>18 THE WITNESS: I don't recall</p> <p>19 specifically --</p> <p>20 MR. LIMBACHER: Excuse me.</p> <p>21 THE WITNESS: Sorry.</p> <p>22 MR. LIMBACHER: I would object to</p> <p>23 the extent it falls outside the scope of</p> <p>24 the topics on which he's been</p>	<p style="text-align: right;">Page 256</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 BY MS. SCULLION:</p> <p>21 Q. Okay. And do you recall that --</p> <p>22 strike that.</p> <p>23 Was it Endo's policy to have</p> <p>24 product specific guides as the foundation for</p>
<p style="text-align: right;">Page 255</p> <p>1 designated.</p> <p>2 You can answer.</p> <p>3 THE WITNESS: I don't recall</p> <p>4 specifically with regards to that</p> <p>5 Lidoderm question.</p> <p>6 BY MS. SCULLION:</p> <p>7 Q. Okay. Just one second. We'll</p> <p>8 come back to that when we find it. You guys</p> <p>9 keep will looking.</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p style="text-align: right;">Page 257</p> <p>1 the promotional materials review process?</p> <p>2 MR. LIMBACHER: Object to form.</p> <p>3 THE WITNESS: I'm not sure what</p> <p>4 that means.</p> <p>5 BY MS. SCULLION:</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

65 (Pages 254 to 257)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 258</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 260</p> <p>1 [REDACTED] 2 [REDACTED] 3 MR. LIMBACHER: Just note my 4 objection. If you're asking these 5 questions in his role as a 30(b)(6) 6 witness, I believe it goes beyond the 7 scope of the topics on which he's been 8 designated. 9 BY MS. SCULLION: 10 Q. Just so you know the reason we 11 disagree with that is, again, one of the topics 12 on which you've been designated are -- is with 13 respect to changes in policies and procedures 14 and reasons therefor, and we believe this 15 document goes directly to questions of changes 16 in policies and procedures that, among other 17 things, impacted efforts to ensure compliance 18 with applicable laws and regulations for the 19 sale, marketing, distribution, et cetera, of 20 opioids. 21 I'm sorry. I was asking on the 22 lower left-hand corner of the first page of the 23 PowerPoint where it says ELC, is that Executive 24 Leadership Committee? A. It was at that point in time,</p>
<p style="text-align: right;">Page 259</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 (Document marked for 10 identification as Endo-Lortie Deposition 11 Exhibit No. 20.) 12 BY MS. SCULLION: 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 261</p> <p>1 yes. 2 Q. Looking at Exhibit 20, do you 3 recall seeing a compliance overview in March of 4 2013? 5 A. I was not a member of ELC at that 6 point, so no. 7 Q. Were you aware that -- looking at 8 this, does this refresh your recollection that 9 compliance overview was undertaken around that 10 time? 11 A. I don't recall. 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>

66 (Pages 258 to 261)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 262</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 264</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 263</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 265</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 BY MS. SCULLION:</p> <p>18 Q. Do you have an understanding of</p> <p>19 the concept of record review in connection with</p> <p>20 compliance?</p> <p>21 A. This is what I'm asking for</p> <p>22 clarification on because I need some help in</p> <p>23 recalling what the definition of that</p> <p>24 specifically is in this context. So if you've</p>

67 (Pages 262 to 265)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 266</p> <p>1 got something, I'd be happy to look at it.</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>Page 268</p> <p>1</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>
<p>Page 267</p> <p>1 Q. Do you know what efforts Endo --</p> <p>2 strike that.</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>Page 269</p> <p>1</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

68 (Pages 266 to 269)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 270</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 272</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 271</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 273</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

69 (Pages 270 to 273)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 274</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 (Document marked for 10 identification as Endo-Lortie Deposition 11 Exhibit No. 21.) 12 BY MS. SCULLION: 13 Q. Okay. Let me show you what's 14 been marked as Exhibit Number 2. 15 And Exhibit Number 21 is 16 marked -- is Bates stamped END00401724, and 17 we've marked it E1604.1 in the upper right-hand 18 corner. 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 276</p> <p>1 my preparation. 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>
<p style="text-align: right;">Page 275</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 I actually only have a question for you about 8 one page of the Health Care Compliance Guide. I 9 take it you did not review this in connection 10 with your preparation for today's deposition? 11 A. I don't recall reviewing it. If 12 you'd like to point me to the page, but I'd 13 still -- 14 Q. Sure. 15 A. -- reserve the ability to 16 understand the context. 17 Q. The page is E1604.18? 18 MR. LIMBACHER: I'm sorry. Which 19 page? 20 MS. SCULLION: 1604.18. 21 BY MS. SCULLION: 22 Q. Are you with me? 23 A. Yeah, I'm just understanding the 24 chapter, and I now recognize I have seen this in</p>	<p style="text-align: right;">Page 277</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>

70 (Pages 274 to 277)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 278</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 280</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 279</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 281</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

71 (Pages 278 to 281)

Highly Confidential - Subject to Further Confidentiality Review

Page 282

1 [REDACTED]
2 [REDACTED]
3 [REDACTED]
4 [REDACTED]
5 [REDACTED]
6 [REDACTED]
7 [REDACTED]
8 [REDACTED]
9 [REDACTED]
10 [REDACTED]
11 [REDACTED]
12 [REDACTED]
13 [REDACTED]
14 [REDACTED]
15 [REDACTED]
16 [REDACTED]
17 [REDACTED]
18 [REDACTED]
19 [REDACTED]
20 MR. LIMBACHER: It's almost an
21 hour, so maybe we'll take a short break.
22 MS. SCULLION: Yeah, that's fine.
23 MR. LIMBACHER: Thank you.
24 THE VIDEOGRAPHER: The time is

Page 283

1 3:35. We are now going off the record.
2 (Brief recess.)
3 THE VIDEOGRAPHER: The time is
4 3:48. We are now back on record.
5 (Document marked for
6 identification as Endo-Lortie Deposition
7 Exhibit No. 22.)
8 BY MS. SCULLION:
9 Q. Mr. Lortie, let me hand you
10 what's been marked as Exhibit Number 22.
11 And Exhibit Number 22 is a copy
12 of the -- of material that your counsel provided
13 to us in advance of your deposition, and it is,
14 to my understanding, a chart showing the claims
15 that we've asked you to speak to in response to
16 topic 13 of the 30(b)(6) notice on the left-hand
17 side, and on the right-hand side are the
18 supporting references for those claims.
19 Mr. Lortie, did you review
20 Exhibit 22 before today's deposition?
21 A. Yes, I did.
22 Q. Do you know who prepared Exhibit
23 22?
24 A. This was prepared by our counsel

Page 284

1 in preparation for this topic.
2 Q. Did you assist in its
3 preparation?
4 A. I did not prepare it. I reviewed
5 it and ensured by checking and referring to some
6 of the references so that I could familiarize
7 myself with the material.
8 Q. Okay. The material listed as
9 supporting references on the right side of
10 Exhibit 22, were those materials that were cited
11 contemporaneously as support for the claims,
12 meaning at the time that the marketing piece
13 listed in the left-hand column of the chart was
14 authorized for use?
15 MR. LIMBACHER: Object to form,
16 outside the scope of the topics on which
17 he's been designated.
18 THE WITNESS: I believe that to
19 be the case, but I'm not sure I
20 personally checked the dates on each
21 one, but that's my understanding.
22 BY MS. SCULLION:
23 Q. Do you have an understanding
24 about whether -- what information exists in

Page 285

1 Endo's records that would allow one to know
2 whether these materials were, in fact, the
3 materials cited contemporaneously to support a
4 claim in a given piece of marketing -- sorry,
5 promotional material?
6 MR. LIMBACHER: Object to form.
7 THE WITNESS: I'm not sure I
8 understand what you're asking.
9 BY MS. SCULLION:
10 [REDACTED]
11 [REDACTED]
12 [REDACTED]
13 [REDACTED]
14 [REDACTED]
15 [REDACTED]
16 [REDACTED]
17 [REDACTED]
18 [REDACTED]
19 [REDACTED]
20 [REDACTED]
21 [REDACTED]
22 [REDACTED]
23 [REDACTED]
24 [REDACTED]





72 (Pages 282 to 285)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 286</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 288</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 287</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 289</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 So if we could go to claim number</p> <p>5 24, which is on page 9 of Exhibit 22. And in</p> <p>6 our request with respect to this claim, we cited</p> <p>7 to a document Bates stamped</p> <p>8 ENDO-CHI_LIT-00538441.</p> <p>9 MS. SCULLION: And do we have</p> <p>10 that, it's E785?</p> <p>11 (Document marked for</p> <p>12 identification as Endo-Lortie Deposition</p> <p>13 Exhibit No. 23.)</p> <p>14 BY MS. SCULLION:</p> <p>15 Q. Let me hand you what's been</p> <p>16 marked as Exhibit 23.</p> <p>17 And Exhibit 23 you'll see does</p> <p>18 bear that Bates number, correct, lower</p> <p>19 right-hand corner?</p> <p>20 A. Yes, it does.</p> <p>21 MR. LIMBACHER: And, counsel,</p> <p>22 just so we're clear, you've been asking</p> <p>23 him questions in his capacity as a</p> <p>24 30(b)(6) witness?</p>

73 (Pages 286 to 289)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 290</p> <p>1 MS. SCULLION: Yes, except to the</p> <p>2 extent that you've objected that it's</p> <p>3 beyond the scope. We'll have to see</p> <p>4 where that comes out.</p> <p>5 BY MS. SCULLION:</p> <p>6 Q. And you'll see in the chart we</p> <p>7 cite to certain statements in this document on</p> <p>8 pages 3 and 4, and if you turn in Exhibit 23 to</p> <p>9 page E785.3, you'll see on the right-hand side</p> <p>10 that is page 3.</p> <p>11 Do you see that?</p> <p>12 A. I see 785.3, yes, page 3, which</p> <p>13 is the column, right.</p> <p>14 Q. Right.</p> <p>15 A. The right-hand column, yep.</p> <p>16 Q. All right. So before we get into</p> <p>17 specifics, if you can turn back to the first</p> <p>18 page of Exhibit 23.</p> <p>19 </p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 292</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15 Q. Okay. And this was one such</p> <p>16 brochure, right?</p> <p>17 A. Yes.</p> <p>18 Q. Okay. And if you'll try and hold</p> <p>19 both Exhibit 23 and 22 open at the same time,</p> <p>20 turning to page 3 of Exhibit 23 of the brochure,</p> <p>21 I just want to try and match up the language on</p> <p>22 the page with the language in the claims chart</p> <p>23 that is Exhibit 22.</p> <p>24 Do you follow what I'm trying to</p>
<p style="text-align: right;">Page 291</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 293</p> <p>1 do?</p> <p>2 A. Yes, I'm doing that in advance.</p> <p>3 </p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

74 (Pages 290 to 293)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 294</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 296</p> <p>1 supporting references and then asking 2 him questions about what is in those 3 supporting references. I believe Josh 4 Davis made it very clear to you in his 5 e-mail of January 6, 2019 that 6 Mr. Lortie was not going to be prepared 7 to speak as a corporate representative 8 in full detail to all substantive or 9 scientific aspects of all support that 10 may be identified in this chart. 11 So if I can have a continuing 12 objection to those types of questions 13 where you're showing him the supporting 14 references and then asking him to match 15 that up with what's in the chart. 16 MS. SCULLION: I hear your 17 objection. You can certainly have it on 18 a continuing basis. I'd just note that 19 our understanding was that although 20 Mr. Lortie might not be prepared to sit 21 here and parse in detail the scientific 22 basis for any particular claim that's 23 cited, that he was to be prepared to 24 speak to the support for those claims.</p>
<p style="text-align: right;">Page 295</p> <p>1 Q. And then we've got a lot of 2 moving pieces here. 3 MS. SCULLION: Can we have the 4 definitions. 5 (Document marked for 6 identification as Endo-Lortie Deposition 7 Exhibit No. 24.) 8 BY MS. SCULLION: 9 Q. I hand you what's been marked as 10 Exhibit 24. 11 A. Should I keep these open or 12 nearby? 13 Q. It probably will be useful. 14 And Exhibit 24 is Bates stamped 15 ENDO-OPIOID_MDL-06233148. Mark that down, 16 Exhibit 24. 17 And Exhibit 24 is the definitions 18 section cited in the claims chart we just looked 19 at, right? 20 A. Yes. 21 Q. Okay. Just one second. 22 MR. LIMBACHER: Jen, just for the 23 record, I want to object to any 24 questions where you are showing him the</p>	<p style="text-align: right;">Page 297</p> <p>1 In fact, Mr. Davis made something 2 of a point about the burden it would be 3 for Mr. Lortie to be prepared on any 4 additional claims because it had taken 5 so much to prepare him to speak to the 6 claims that we did have in the chart. 7 BY MS. SCULLION: 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>





75 (Pages 294 to 297)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 298</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 300</p> <p>1 BY MS. SCULLION:</p> <p>2 Q. Right.</p> <p>3 A. -- you're correct, the authors</p> <p>4 did not lift the entirety of the definitions as</p> <p>5 the claim or as support.</p> <p>6 Q. Right.</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 299</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 THE WITNESS: There are many</p> <p>23 paragraphs that follow the cited</p> <p>24 reference so --</p>	<p>Page 301</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

76 (Pages 298 to 301)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 302</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 304</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 
<p>Page 303</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 305</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 

77 (Pages 302 to 305)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 306</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 308</p> <p>1 That was not the question.</p> <p>2 BY MS. SCULLION:</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 307</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 309</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

78 (Pages 306 to 309)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 310</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 312</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 A. Sorry. Let me just catch up 6 here. 7 Q. Sure, the bottom of page 3. 8 A. It's actually in the middle of 9 page 3, I think, right? 10 Q. I'm looking at the page that's 11 labeled in the lower left-hand corner 3 of 4, 12 and underneath it says the date on which it was 13 approved by the AAPM Board of Directors, 14 February 13th, 2001. 15 Do you see that? 16 A. Okay. I'm sorry I was on the 17 cover where the three organizations were listed. 18 I think they're probably the same ones, but so 19 I'll go to your page. 20 Q. Let's -- I want to go -- be 21 specific on page 3 of 4, you see after the 22 definitions it says "Approved by the AAPM Board 23 of Directors on February 13, 2001." 24 A. Yes.</p>
<p style="text-align: right;">Page 311</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 313</p> <p>1 Q. And the AAPM is American Academy 2 of Pain Medicine, right? 3 A. Yes. 4 Q. And the American Academy of Pain 5 Medicine was recognized as the industry-friendly 6 organization, correct? 7 MR. LIMBACHER: Object to form. 8 THE WITNESS: I don't know. I 9 don't know that. 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>

79 (Pages 310 to 313)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 314</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 316</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 315</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 317</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
















80 (Pages 314 to 317)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 318</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 320</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 319</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 321</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 MR. LIMBACHER: Object to form</p> <p>4 and, again, object as outside the scope</p> <p>5 of the topics on which he has been</p> <p>6 designated.</p> <p>7 The subject of Endo's</p> <p>8 relationship with the American Academy</p> <p>9 of Pain Medicine is specifically</p> <p>10 referenced in topic number 36 of your</p> <p>11 30(b)(6) deposition notice, and this</p> <p>12 witness has not been designated to</p> <p>13 testify with regard to topic number 36.</p> <p>14 MS. SCULLION: Counsel, objection</p> <p>15 to beyond the scope is just fine. I</p> <p>16 think you're now crossing a line to try</p> <p>17 to coach the witness.</p> <p>18 MR. LIMBACHER: I'm not coaching</p> <p>19 the witness.</p> <p>20 MS. SCULLION: It's -- it is</p> <p>21 beyond --</p> <p>22 MR. LIMBACHER: I'm trying to</p> <p>23 gently suggest to you, counsel --</p> <p>24 MS. SCULLION: Counsel, if you</p>

81 (Pages 318 to 321)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 322</p> <p>1 let me finish my statement, I let you 2 finish yours. 3 MR. LIMBACHER: -- that you are 4 asking questions that go well beyond the 5 scope of what you know this witness has 6 been designated for. 7 MS. SCULLION: And you know that 8 we asked for this witness both with 9 respect to his 30(b)(6) topics and in 10 his personal capacity. If it is indeed 11 beyond the topic, which I don't agree, 12 he's perfectly welcome to answer the 13 questions in his personal capacity. 14 MR. LIMBACHER: Well, you're not 15 going to get 14 hours of questioning of 16 this witness in his individual capacity. 17 You have to make a decision as to 18 whether or not you're asking him 19 questions in his role as a 30(b)(6) 20 witness or not. We have an agreement 21 that we memorialized at the outset of 22 this deposition that unless you make it 23 clear that you are asking him questions 24 about 30(b)(6), then he's answering</p>	<p style="text-align: right;">Page 324</p> <p>1 Exhibit 24, correct? 2 A. I'm looking for that. 3 Q. Sure. At the very bottom 4 underneath the approval by the AAPM, you next 5 have approved by the APS Board of Directors. 6 Do you see that? 7 A. And then under that it says 8 American Pain Society, correct? 9 Q. Correct. 10 MR. LIMBACHER: Same objections, 11 counsel. And, again, American Pain 12 Society is specifically referenced in 13 topic 36. 14 BY MS. SCULLION: 15 Q. And then if you go back to 16 Exhibit 25, you also see that American Pain 17 Society is also identified as a tier one 18 advocate, and that is at -- if you go to page -- 19 where we were -- page 15, it says "First Tier 20 Professional Pain Management Advocacy 21 Organizations," right, so it's going to be 22 listing multiple organizations. The first one 23 we've been through the American Academy of Pain 24 Medicine.</p>
<p style="text-align: right;">Page 323</p> <p>1 these questions in his role as a fact 2 witness, but you have told us that all 3 of the questions with regard to this 4 chart are in his capacity as a 30(b)(6) 5 witness, but the questions you are now 6 asking with regard to the American 7 Academy of Pain Medicine fall well 8 outside the scope of the topics on which 9 he has been designated and, in fact, are 10 specifically referenced in topic 36. 11 MS. SCULLION: Right, so we 12 disagree. I think they're also 13 encompassed within topic 37. I suggest 14 we just -- you just say object to the 15 scope and we deal with it at some other 16 time if needed, but let's -- I think we 17 should move on with the testimony. 18 BY MS. SCULLION: 19 Q. And then one of the other 20 organizations, going back to Exhibit 24, which 21 is the definitions and consensus statement, one 22 of the other organizations that approved the 23 definitions that you've cited was the American 24 Pain Society, and that's at page 3 of 4 of</p>	<p style="text-align: right;">Page 325</p> <p>1 Go to the next page, the next of 2 those first tier professional pain management 3 advocacy organizations is the American Pain 4 Society, correct? 5 MR. LIMBACHER: Same objections, 6 beyond the scope. 7 THE WITNESS: On top of page 16, 8 I see "American Pain Society," yes. 9 BY MS. SCULLION: 10  11  12  13  14  15  16  17  18  19  20  21  22  23  24 </p>





82 (Pages 322 to 325)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 326</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 MR. LIMBACHER: Same objections 23 and move to strike. 24 BY MS. SCULLION:</p>	<p style="text-align: right;">Page 328</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>
<p style="text-align: right;">Page 327</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 329</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 MS. SCULLION: Okay. Can we have 12 the binder of labels. Can we mark these 13 as the next four exhibits. 14 (Documents marked for 15 identification as Endo-Lortie 16 Deposition Exhibit Nos. 26, 27, 28 and 17 29.) 18 BY MS. SCULLION: 19 Q. I'm going to hand you a binder 20 with exhibits that have been marked Exhibits 21 27 -- 22 A. Mine starts with 26. 23 Q. Twenty-six, that's what I got 24 wrong, thank you, 26, 27, 28 and 29.</p>





83 (Pages 326 to 329)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 330</p> <p>1 And let's start with Exhibit 26, 2 which is Bates stamped ENDO-OPIOID_MDL00291042, 3 and we've marked it in the upper right-hand 4 corner E1407.1. 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 332</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 
<p>Page 331</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 333</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 

84 (Pages 330 to 333)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 334</p> <p>1 BY MS. SCULLION: 2 Q. And then if you go to Exhibit 3 Number 27, which is next in your binder, and 4 it's Bates stamped ENDO-OPIOID_MDL-00299099, in 5 the upper right-hand corner we've labeled it 6 E1408. 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 336</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 
<p>Page 335</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 337</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 





85 (Pages 334 to 337)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 338</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 stopping point?</p> <p>17 MS. SCULLION: Yeah, we can stop</p> <p>18 there.</p> <p>19 MR. LIMBACHER: Thank you.</p> <p>20 THE VIDEOGRAPHER: The time is</p> <p>21 4:43. We're going off the record.</p> <p>22 (Brief recess.)</p> <p>23 THE VIDEOGRAPHER: The time is</p> <p>24 5:00 p.m. We are now back on the</p>	<p>Page 340</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 339</p> <p>1 record.</p> <p>2 BY MS. SCULLION:</p> <p>3 Q. Mr. Lortie, welcome back. I'm</p> <p>4 going to ask you some questions in your personal</p> <p>5 capacity.</p> <p>6 A. Okay.</p> <p>7 Q. Sure is good news to counsel's</p> <p>8 ears at this point.</p> <p>9 Mr. Lortie, when you were with</p> <p>10 Endo, you recall that Endo -- sorry, Endo sought</p> <p>11 FDA approval for a reformulated version of Opana</p> <p>12 ER?</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 341</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

86 (Pages 338 to 341)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 342</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 344</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 
<p>Page 343</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 	<p>Page 345</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p> 

87 (Pages 342 to 345)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 346</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 identification as Endo-Lortie Deposition</p> <p>23 Exhibit No. 30.)</p> <p>24 BY MS. SCULLION:</p>	<p>Page 348</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 347</p> <p>1 Q. Okay. Let me show you what's</p> <p>2 been marked as E14 -- I'm sorry, Exhibit 30.</p> <p>3 Exhibit 30 is Bates stamped</p> <p>4 ENDO-CHI_LIT00206530, and it's stamped in upper</p> <p>5 right-hand corner E1497.</p> <p>6 And do you recognize Exhibit 30</p> <p>7 as an e-mail chain, which includes an e-mail</p> <p>8 from you to Kristin Vitanza dated May 15th, 2012</p> <p>9 concerning the new language for the OER selling</p> <p>10 piece?</p> <p>11 MR. LIMBACHER: Take your time</p> <p>12 and review the document.</p> <p>13 THE WITNESS: You said 1497,</p> <p>14 correct?</p> <p>15 MS. SCULLION: Yeah.</p> <p>16 THE WITNESS: So let me just take</p> <p>17 a look from the beginning to orient</p> <p>18 myself.</p> <p>19 (Witness reviews document.)</p> <p>20 Okay. Thank you. I've reviewed</p> <p>21 it.</p> <p>22 BY MS. SCULLION:</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 349</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

88 (Pages 346 to 349)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 350</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 352</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 351</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 MS. SCULLION: Let's look at</p> <p>6 what's been marked as Exhibit 31.</p> <p>7 (Document marked for</p> <p>8 identification as Endo-Lortie Deposition</p> <p>9 Exhibit No. 31.)</p> <p>10 BY MS. SCULLION:</p> <p>11 Q. And Exhibit 31 is Bates stamped</p> <p>12 ENDO-CHI_LIT00110100, and we've marked it E1482</p> <p>13 in the upper right-hand corner.</p> <p>14 A. Yes.</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 353</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>





89 (Pages 350 to 353)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 354</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 BY MS. SCULLION:</p> <p>5 Q. Now, this is in May of 2012,</p> <p>6 correct?</p> <p>7 A. May 5th, in fact, yes.</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 356</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 355</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 357</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 MS. SCULLION: Can we have E1501</p> <p>11 and E1498.</p> <p>12 (Document marked for</p> <p>13 identification as Endo-Lortie Deposition</p> <p>14 Exhibit No. 32.)</p> <p>15 BY MS. SCULLION:</p> <p>16 Q. I'll hand you what's been marked</p> <p>17 as Exhibit Number 32.</p> <p>18 And Exhibit Number 32 is Bates</p> <p>19 stamped END00095867, and we've marked it E1501.</p> <p>20 And, Mr. Lortie, do you see that</p> <p>21 Exhibit 32 is a series of e-mails referencing</p> <p>22 OER pharmacy market research revised report?</p> <p>23 A. I see that at the top. I'm just</p> <p>24 going to, if it's okay, take a moment to look</p>

90 (Pages 354 to 357)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 358</p> <p>1 through the e-mails here.</p> <p>2 Q. Yeah.</p> <p>3 A. (Witness reviews document.)</p> <p>4 Okay. Thank you. I've taken a</p> <p>5 look.</p> <p>6 </p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 360</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>
<p style="text-align: right;">Page 359</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p style="text-align: right;">Page 361</p> <p>1 </p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

91 (Pages 358 to 361)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 362</p> <p>1 BY MS. SCULLION:</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>Page 364</p> <p>1</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20 Q. I hand you what I marked as</p> <p>21 Exhibit -- I think it's 33, right?</p> <p>22 A. Thirty-three, yes.</p> <p>23 (Document marked for</p> <p>24 identification as Endo-Lortie Deposition</p>
<p>Page 363</p> <p>1</p> <p>2</p> <p>3</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>	<p>Page 365</p> <p>1 Exhibit No. 33.)</p> <p>2 BY MS. SCULLION:</p> <p>3 Q. Yeah, Exhibit 33, a document</p> <p>4 Bates stamped END00465847, and we've labeled it</p> <p>5 E1498 in the top right-hand corner.</p> <p>6 Do you have Exhibit 33?</p> <p>7 A. Yes.</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

92 (Pages 362 to 365)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 366</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 368</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 MS. SCULLION: Can I have Exhibit</p> <p>10 1409, E1409.</p> <p>11 BY MS. SCULLION:</p> <p>12 Q. Let me hand you what has been</p> <p>13 marked as Exhibit -- sorry, I didn't keep track.</p> <p>14 A. Thirty-four.</p> <p>15 (Document marked for</p> <p>16 identification as Endo-Lortie Deposition</p> <p>17 Exhibit No. 34.)</p> <p>18 BY MS. SCULLION:</p> <p>19 Q. Thank you, 34, which is Bates</p> <p>20 stamped ENDO-CHI_LIT-00135664, and we've marked</p> <p>21 in the upper right-hand corner E1409. If you'll</p> <p>22 turn to the first page of the PowerPoint, which</p> <p>23 is E1409.3, this is reporting on "Opana ER</p> <p>24 Crush-Resistant Formulation Research, Wave 5,</p>
<p>Page 367</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 369</p> <p>1 Qualitative Interviews" dated December 13th,</p> <p>2 2012, correct?</p> <p>3 A. Yes. I'll just take a minute, if</p> <p>4 it's okay, and look through the deck.</p> <p>5 Q. Sure.</p> <p>6 A. (Witness reviews document.)</p> <p>7 Okay. I've taken a look at most</p> <p>8 of the pages.</p> <p>9 Q. Okay. And Exhibit 34 is</p> <p>10 reporting on market research that the KJT Group</p> <p>11 did on behalf of Endo, correct?</p> <p>12 A. Apparently, yes.</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

93 (Pages 366 to 369)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 370</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 MR. LIMBACHER: I apologize for 23 interrupting, but my real time is not 24 working. I don't know if I did</p>	<p style="text-align: right;">Page 372</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>
<p style="text-align: right;">Page 371</p> <p>1 something or what, I apologize, but I 2 need a little technical help. 3 THE VIDEOGRAPHER: Off the 4 record, 5:35. 5 (Pause.) 6 THE VIDEOGRAPHER: It is 5:36. 7 We are back on the record. 8 BY MS. SCULLION: 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 373</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>

94 (Pages 370 to 373)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 374</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 376</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 375</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 377</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 MS. SCULLION: So do we have the</p> <p>9 press release?</p> <p>10 (Document marked for</p> <p>11 identification as Endo-Lortie Deposition</p> <p>12 Exhibit No. 35.)</p> <p>13 BY MS. SCULLION:</p> <p>14 Q. Hand you what's been marked as</p> <p>15 Exhibit 35.</p> <p>16 And Exhibit 35 is a copy of a --</p> <p>17 publicly available on Endo's website -- a copy</p> <p>18 of a November 30th, 2012 press release entailed</p> <p>19 "Endo Health Solutions Sues FDA to Protect</p> <p>20 Consumers from Non-Tamper Resistant</p> <p>21 Oxymorphone."</p> <p>22 Did I read that correctly?</p> <p>23 A. Yes, that's the headline.</p> <p>24 Q. And the subheadline in the press</p>

95 (Pages 374 to 377)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 378</p> <p>1 release says, "Surveillance data show dramatic 2 decrease in abuse rates of reformulated Opana ER 3 designed to be crush-resistant when compared to 4 non-tamper resistant formulation." 5 Did I read that correctly? 6 A. You did. 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p>	<p style="text-align: right;">Page 380</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p>
<p style="text-align: right;">Page 379</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p>	<p style="text-align: right;">Page 381</p> <p>1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24</p>

96 (Pages 378 to 381)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 382</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 384</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 383</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 385</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

97 (Pages 382 to 385)

Highly Confidential - Subject to Further Confidentiality Review

<p style="text-align: right;">Page 386</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 388</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 [REDACTED] 8 [REDACTED] 9 [REDACTED] 10 [REDACTED] 11 [REDACTED] 12 [REDACTED] 13 [REDACTED] 14 [REDACTED] 15 [REDACTED] 16 [REDACTED] 17 [REDACTED] 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 Q. Okay. 22 MS. SCULLION: Go to E959. 23 (Document marked for 24 identification as Endo-Lortie Deposition</p>
<p style="text-align: right;">Page 387</p> <p>1 [REDACTED] 2 [REDACTED] 3 [REDACTED] 4 [REDACTED] 5 [REDACTED] 6 [REDACTED] 7 MS. SCULLION: And then can we 8 have E959, 1494, 1483. 9 BY MS. SCULLION: 10 Q. Now, the other way that Endo -- 11 another way that Endo got out the message that 12 the reformulated version of Opana ER was crush 13 resistant was through a formulary -- I'm 14 sorry -- compendia submissions, correct? 15 MR. LIMBACHER: Object to form. 16 THE WITNESS: No, that's not 17 correct. 18 BY MS. SCULLION: 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>	<p style="text-align: right;">Page 389</p> <p>1 Exhibit No. 36.) 2 BY MS. SCULLION: 3 Q. I've handed you what's been 4 marked as Exhibit 36. I'll look at the Bates 5 Number in one second. 6 MR. LIMBACHER: Take your time 7 and review the document. 8 (Witness reviews document.) 9 BY MS. SCULLION: 10 Q. Have you had a chance to review 11 the exhibit? 12 A. I have. Just I'm noting page 2, 13 959.2 is blank. Is that intentionally blank? 14 Q. Yes. 15 A. I just wanted to make sure I'm 16 not missing an e-mail or something. 17 Q. No, no, you're not. 18 [REDACTED] 19 [REDACTED] 20 [REDACTED] 21 [REDACTED] 22 [REDACTED] 23 [REDACTED] 24 [REDACTED]</p>

98 (Pages 386 to 389)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 390</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 392</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 391</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 393</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

99 (Pages 390 to 393)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 394</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 396</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 395</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 397</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

100 (Pages 394 to 397)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 398</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 400</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 399</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 identification as Endo-Lortie Deposition</p> <p>9 Exhibit No. 37.)</p> <p>10 BY MS. SCULLION:</p> <p>11 Q. Let me hand you what's been</p> <p>12 marked as Exhibit Number 37.</p> <p>13 And Exhibit 37 is Bates stamped</p> <p>14 END00121820, and we've marked it E1494 at the</p> <p>15 top.</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 401</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

101 (Pages 398 to 401)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 402</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 404</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 403</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 break. We have the document with us</p> <p>9 before. Let's go back to that.</p> <p>10 THE VIDEOGRAPHER: The time is</p> <p>11 6:10. We are going off the record.</p> <p>12 (Brief recess.)</p> <p>13 (Document marked for</p> <p>14 identification as Endo-Lortie Deposition</p> <p>15 Exhibit No. 38.)</p> <p>16 THE VIDEOGRAPHER: We are back on</p> <p>17 the record at 6:22.</p> <p>18 BY MS. SCULLION:</p> <p>19 Q. Mr. Lortie, we've handed you off</p> <p>20 the record and provided to counsel a copy of</p> <p>21 Exhibit Number 38, which is Bates stamped</p> <p>22 ENDO-CHI_LIT-00467546, and we've Bates stamped</p> <p>23 it -- or, sorry, stamped the top right-hand</p> <p>24 corner E119.</p>	<p>Page 405</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 406</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 408</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 407</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 409</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

103 (Pages 406 to 409)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 410</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 412</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>
<p>Page 411</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 413</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>

104 (Pages 410 to 413)

Highly Confidential - Subject to Further Confidentiality Review

<p>Page 414</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 416</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 MS. SCULLION: So we're going to</p> <p>8 end for today. We have gone past 6:00.</p> <p>9 We've tried to do, frankly, a good unit,</p> <p>10 but we're going to end for today and</p> <p>11 resume the deposition tomorrow at</p> <p>12 approximately 2:30, if that is</p> <p>13 convenient to you?</p> <p>14 THE WITNESS: Yes, thank you,</p> <p>15 that will work.</p> <p>16 MR. LIMBACHER: I just want to be</p> <p>17 clear before we all leave here today</p> <p>18 that it's our position that we should be</p> <p>19 able to get this deposition completed</p> <p>20 tomorrow. I would ask that everybody</p> <p>21 use their best efforts to get it</p> <p>22 completed tomorrow.</p> <p>23 And do you have any expectation</p> <p>24 as to how much more you have?</p>
<p>Page 415</p> <p>1 [REDACTED]</p> <p>2 [REDACTED]</p> <p>3 [REDACTED]</p> <p>4 [REDACTED]</p> <p>5 [REDACTED]</p> <p>6 [REDACTED]</p> <p>7 [REDACTED]</p> <p>8 [REDACTED]</p> <p>9 [REDACTED]</p> <p>10 [REDACTED]</p> <p>11 [REDACTED]</p> <p>12 [REDACTED]</p> <p>13 [REDACTED]</p> <p>14 [REDACTED]</p> <p>15 [REDACTED]</p> <p>16 [REDACTED]</p> <p>17 [REDACTED]</p> <p>18 [REDACTED]</p> <p>19 [REDACTED]</p> <p>20 [REDACTED]</p> <p>21 [REDACTED]</p> <p>22 [REDACTED]</p> <p>23 [REDACTED]</p> <p>24 [REDACTED]</p>	<p>Page 417</p> <p>1 MS. SCULLION: I do not, sitting</p> <p>2 here today, but we can talk tomorrow. I</p> <p>3 would anticipate that our portion of the</p> <p>4 deposition would be done tomorrow. I</p> <p>5 know that counsel from Tennessee is also</p> <p>6 here, so I suspect he'll have some</p> <p>7 examination, as you may as well.</p> <p>8 MR. LIMBACHER: Understood.</p> <p>9 Thank you.</p> <p>10 THE VIDEOGRAPHER: That concludes</p> <p>11 today's testimony. The time is</p> <p>12 6:38 p m.</p> <p>13 (Witness excused.)</p> <p>14 ---</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p>

105 (Pages 414 to 417)

Highly Confidential - Subject to Further Confidentiality Review

Page 418		Page 420	
1	CERTIFICATION	1	ACKNOWLEDGMENT OF DEPONENT
2	I, MARGARET M. REIHL, a	2	
3	Registered Professional Reporter,	3	I, BRIAN LORTIE, do hereby
4	Certified Realtime Reporter, Certified	4	certify that I have read the foregoing
5	Shorthand Reporter, Certified LiveNote	5	pages, and that the same is a correct
6	Reporter and Notary Public, do hereby	6	transcription of the answers given by me
7	certify that the foregoing is a true and	7	to the questions therein propounded,
8	accurate transcript of the testimony as	8	except for the corrections or changes in
9	taken stenographically by and before me	9	form or substance, if any, noted in the
10	at the time, place, and on the date	10	attached Errata Sheet.
11	hereinbefore set forth.	11	
12	I DO FURTHER CERTIFY that I	12	
13	am neither a relative nor employee nor	13	
14	attorney nor counsel of any of the	14	BRIAN LORTIE DATE
15	parties to this action, and that I am	15	
16	neither a relative nor employee of such	16	Subscribed and sworn to before me this
17	attorney or counsel, and that I am not	17	_____ day of _____, 2018.
18	financially interested in the action.	18	My commission expires: _____
19		19	_____
20		20	Notary Public
21	-----	21	
22	Margaret M. Reihl, RPR, CRR, CLR	22	
23	CSR #XI01497 Notary Public	23	
24		24	

Page 419	
1	- - - - -
2	ERRATA
3	- - - - -
4	PAGE LINE CHANGE
5	_____
6	REASON: _____
7	_____
8	REASON: _____
9	_____
10	REASON: _____
11	_____
12	REASON: _____
13	_____
14	REASON: _____
15	_____
16	REASON: _____
17	_____
18	REASON: _____
19	_____
20	REASON: _____
21	_____
22	REASON: _____
23	_____
24	REASON: _____